<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Vaccines for the common cold - Montesinos-Guevara, C - 2022 | Cochrane Library</title> <meta content="Vaccines for the common cold - Montesinos-Guevara, C - 2022 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002190.pub6/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Vaccines for the common cold - Montesinos-Guevara, C - 2022 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002190.pub6/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD002190.pub6" name="dc.identifier" scheme="DOI"/> <meta content="Vaccines for the common cold" name="citation_title"/> <meta content="Camila Montesinos-Guevara" name="citation_author"/> <meta content="Universidad UTE" name="citation_author_institution"/> <meta content="Diana Buitrago-Garcia" name="citation_author"/> <meta content="University of Bern" name="citation_author_institution"/> <meta content="Maria L Felix" name="citation_author"/> <meta content="Universidad UTE" name="citation_author_institution"/> <meta content="Claudia V Guerra" name="citation_author"/> <meta content="Universidad UTE" name="citation_author_institution"/> <meta content="Ricardo Hidalgo" name="citation_author"/> <meta content="Universidad UTE" name="citation_author_institution"/> <meta content="Maria JosÃ© Martinez-Zapata" name="citation_author"/> <meta content="Daniel Simancas-Racines" name="citation_author"/> <meta content="Universidad UTE" name="citation_author_institution"/> <meta content="danielsimancas10@gmail.com" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="12" name="citation_issue"/> <meta content="10.1002/14651858.CD002190.pub6" name="citation_doi"/> <meta content="2022" name="citation_date"/> <meta content="2022/12/14" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002190.pub6/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002190.pub6/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002190.pub6/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Adenovirus Vaccines [adverse effects]; *Common Cold [prevention &amp; control]; Incidence; Randomized Controlled Trials as Topic; Systematic Reviews as Topic; Vaccines, Attenuated [adverse effects]" name="citation_keywords"/> <meta content="" name="citation_fulltext_world_readable"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002190.pub6&amp;doi=10.1002/14651858.CD002190.pub6&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002190.pub6&amp;doi=10.1002/14651858.CD002190.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002190.pub6&amp;doi=10.1002/14651858.CD002190.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002190.pub6&amp;doi=10.1002/14651858.CD002190.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002190.pub6&amp;doi=10.1002/14651858.CD002190.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002190.pub6&amp;doi=10.1002/14651858.CD002190.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002190.pub6&amp;doi=10.1002/14651858.CD002190.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002190.pub6&amp;doi=10.1002/14651858.CD002190.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002190.pub6&amp;doi=10.1002/14651858.CD002190.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002190.pub6&amp;doi=10.1002/14651858.CD002190.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002190.pub6&amp;doi=10.1002/14651858.CD002190.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002190.pub6&amp;doi=10.1002/14651858.CD002190.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002190.pub6&amp;doi=10.1002/14651858.CD002190.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002190.pub6&amp;doi=10.1002/14651858.CD002190.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002190.pub6&amp;doi=10.1002/14651858.CD002190.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002190.pub6&amp;doi=10.1002/14651858.CD002190.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002190.pub6&amp;doi=10.1002/14651858.CD002190.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002190.pub6&amp;doi=10.1002/14651858.CD002190.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002190.pub6&amp;doi=10.1002/14651858.CD002190.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002190.pub6&amp;doi=10.1002/14651858.CD002190.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002190.pub6&amp;doi=10.1002/14651858.CD002190.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002190.pub6&amp;doi=10.1002/14651858.CD002190.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002190.pub6&amp;doi=10.1002/14651858.CD002190.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="Qh5938oe";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD002190\x2epub6\x26doi\x3d10\x2e1002\x2f14651858\x2eCD002190\x2epub6\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002190\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002190\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANT","ko","th","ms","ja","hr","fa","fr","pl"],languageCode:"en",accessStatus:"open-access",doi:"10.1002/14651858.CD002190.pub6",title:"Vaccines for the common cold",firstPublishedDate:"Dec 14, 2022 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Acute Respiratory Infections Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Qh5938oe&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002190.pub6&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD002190.pub6';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> EspaÃ±ol </option> <option class="content-language-option" data-languagecode="fa" value="fa"> ÙØ§Ø±Ø³Û </option> <option class="content-language-option" data-languagecode="fr" value="fr"> FranÃ§ais </option> <option class="content-language-option" data-languagecode="hi" value="hi"> à¤¹à¤¿à¤¨à¥à¤¦à¥ </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> æ¥æ¬èª </option> <option class="content-language-option" data-languagecode="ko" value="ko"> íêµ­ì´ </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> PortuguÃªs </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Ð ÑÑÑÐºÐ¸Ð¹ </option> <option class="content-language-option" data-languagecode="ro" value="ro"> RomÃ¢nÄ </option> <option class="content-language-option" data-languagecode="ta" value="ta"> à®¤à®®à®¿à®´à¯ </option> <option class="content-language-option" data-languagecode="th" value="th"> à¸ à¸²à¸©à¸²à¹à¸à¸¢ </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> ç¹é«ä¸­æ </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> ç®ä½ä¸­æ </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD002190.pub6/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD002190.pub6/full/es"> EspaÃ±ol </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002190.pub6%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD002190.pub6/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD002190.pub6/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD002190.pub6/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD002190.pub6/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD002190.PUB6" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;ÚÚ©ÛØ¯Ù&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;RÃ©sumÃ© scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;ì´ë¡&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;à¸à¸à¸à¸±à¸à¸¢à¹à¸­&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en tÃ©rminos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;Ø®ÙØ§ØµÙ Ø¨Ù Ø²Ø¨Ø§Ù Ø³Ø§Ø¯Ù&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;RÃ©sumÃ© simplifiÃ©&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;LaiÄki saÅ¾etak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;ä¸è¬èªè¨³&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;ì¬ì´ ë§ ìì½&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym jÄzykiem&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;à¸à¹à¹à¸­à¸ªà¸£à¸¸à¸à¸ à¸²à¸©à¸²à¸à¸£à¸£à¸¡à¸à¸²&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;æ·ºé¡¯ææçå£èªçµè«&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD002190.pub6/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD002190.PUB6" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD002190.pub6/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD002190.pub6/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views:Â </span> <span>4556 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD002190.pub6" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002190.pub6/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002190.pub6/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002190.pub6/full#CD002190-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002190.pub6/full#CD002190-sec-0061"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002190.pub6/full#CD002190-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002190.pub6/full#CD002190-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002190.pub6/full#CD002190-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002190.pub6/full#CD002190-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002190.pub6/full#CD002190-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002190.pub6/full#CD002190-sec-0055"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD002190.pub6/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002190.pub6/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002190.pub6/appendices#CD002190-sec-0066"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002190.pub6/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002190.pub6/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD002190.pub6/media/CDSR/CD002190/supinfo/CD002190StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD002190.pub6/media/CDSR/CD002190/supinfo/CD002190StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002190.pub6/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002190.pub6/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002190.pub6/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD002190.pub6/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD002190.pub6/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD002190.pub6/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright Â© 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley &amp; Sons, Ltd. on behalf of The Cochrane Collaboration." data-creative-commons="true" href="/cdsr/doi/10.1002/14651858.CD002190.pub6/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Vaccines for the common cold</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002190.pub6/information#CD002190-cr-0004">Camila Montesinos-Guevara</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002190.pub6/information#CD002190-cr-0005">Diana Buitrago-Garcia</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002190.pub6/information#CD002190-cr-0006">Maria L Felix</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002190.pub6/information#CD002190-cr-0007">Claudia V Guerra</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002190.pub6/information#CD002190-cr-0008">Ricardo Hidalgo</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002190.pub6/information#CD002190-cr-0009">Maria JosÃ© Martinez-Zapata</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002190.pub6/information#CD002190-cr-0010"><i class="icon corresponding-author fa fa-envelope"></i>Daniel Simancas-Racines</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD002190.pub6/information/en#CD002190-sec-0078">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 14 December 2022 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD002190.pub6/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD002190.pub6">https://doi.org/10.1002/14651858.CD002190.pub6</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD002190-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002190-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD002190-abs-0016">EspaÃ±ol</a> </li> <li class="section-language"> <a class="" href="full/fa#CD002190-abs-0011">ÙØ§Ø±Ø³Û</a> </li> <li class="section-language"> <a class="" href="full/fr#CD002190-abs-0013">FranÃ§ais</a> </li> <li class="section-language"> <a class="" href="full/ko#CD002190-abs-0004">íêµ­ì´</a> </li> <li class="section-language"> <a class="" href="full/th#CD002190-abs-0006">à¸ à¸²à¸©à¸²à¹à¸à¸¢</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD002190-abs-0001" lang="en"> <section id="CD002190-sec-0001"> <h3 class="title" id="CD002190-sec-0001">Background</h3> <p>The common cold is a spontaneously remitting infection of the upper respiratory tract, characterised by a runny nose, nasal congestion, sneezing, cough, malaise, sore throat, and fever (usually &lt; 37.8 ÂºC). Whilst the common cold is generally not harmful, it is a cause of economic burden due to school and work absenteeism. In the United States, economic loss due to the common cold is estimated at more than USD 40 billion per year, including an estimate of 70 million workdays missed by employees, 189 million school days missed by children, and 126 million workdays missed by parents caring for children with a cold. Additionally, data from Europe show that the total cost per episode may be up to EUR 1102. There is also a large expenditure due to inappropriate antimicrobial prescription. Vaccine development for the common cold has been difficult due to antigenic variability of the common cold viruses; even bacteria can act as infective agents. Uncertainty remains regarding the efficacy and safety of interventions for preventing the common cold in healthy people, thus we performed an update of this Cochrane Review, which was first published in 2011 and updated in 2013 and 2017. </p> </section> <section id="CD002190-sec-0002"> <h3 class="title" id="CD002190-sec-0002">Objectives</h3> <p>To assess the clinical effectiveness and safety of vaccines for preventing the common cold in healthy people. </p> </section> <section id="CD002190-sec-0003"> <h3 class="title" id="CD002190-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (April 2022), MEDLINE (1948 to April 2022), Embase (1974 to April 2022), CINAHL (1981 to April 2022), and LILACS (1982 to April 2022). We also searched three trials registers for ongoing studies, and four websites for additional trials (April 2022). We did not impose any language or date restrictions. </p> </section> <section id="CD002190-sec-0004"> <h3 class="title" id="CD002190-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) of any virus vaccine compared with placebo to prevent the common cold in healthy people. </p> </section> <section id="CD002190-sec-0005"> <h3 class="title" id="CD002190-sec-0005">Data collection and analysis</h3> <p>We used Cochraneâs Screen4Me workflow to assess the initial search results. Four review authors independently performed title and abstract screening to identify potentially relevant studies. We retrieved the fullâtext articles for those studies deemed potentially relevant, and the review authors independently screened the fullâtext reports for inclusion in the review, recording reasons for exclusion of the excluded studies. Any disagreements were resolved by discussion or by consulting a third review author when needed. Two review authors independently collected data on a data extraction form, resolving any disagreements by consensus or by involving a third review author. We doubleâchecked data transferred into Review Manager 5 software. Three review authors independently assessed risk of bias using RoB 1 tool as outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions.</i> We carried out statistical analysis using Review Manager 5. We did not conduct a metaâanalysis, and we did not assess publication bias. We used GRADEpro GDT software to assess the certainty of the evidence and to create a summary of findings table.Â  </p> </section> <section id="CD002190-sec-0006"> <h3 class="title" id="CD002190-sec-0006">Main results</h3> <p>We did not identify any new RCTs for inclusion in this update. This review includes one RCT conducted in 1965 with an overall high risk of bias. The RCT included 2307 healthy young men in a military facility, all of whom were included in the analyses, and compared the effect of three adenovirus vaccines (live, inactivated type 4, and inactivated type 4 and 7) against a placebo (injection of physiological saline or gelatin capsule). There were 13 (1.14%) events in 1139 participants in the vaccine group, and 14 (1.19%) events in 1168 participants in the placebo group. Overall, we do not know if there is a difference between the adenovirus vaccine and placebo in reducing the incidence of the common cold (risk ratio 0.95, 95% confidence interval 0.45 to 2.02; very lowâcertainty evidence). Furthermore, no difference in adverse events when comparing live vaccine preparation with placebo was reported. We downgraded the certainty of the evidence to very low due to unclear risk of bias, indirectness because the population of this study was only young men, and imprecision because confidence intervals were wide and the number of events was low. The included study did not assess vaccineârelated or allâcause mortality.Â  </p> </section> <section id="CD002190-sec-0007"> <h3 class="title" id="CD002190-sec-0007">Authors' conclusions</h3> <p>This Cochrane Review was based on one study with very lowâcertainty evidence, which showed that there may be no difference between the adenovirus vaccine and placebo in reducing the incidence of the common cold. We identified a need for wellâdesigned, adequately powered RCTs to investigate vaccines for the common cold in healthy people. Future trials on interventions for preventing the common cold should assess a variety of virus vaccines for this condition, and should measure such outcomes as common cold incidence, vaccine safety, and mortality (allâcause and related to the vaccine). </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD002190-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002190-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD002190-abs-0017">EspaÃ±ol</a> </li> <li class="section-language"> <a class="" href="full/fa#CD002190-abs-0012">ÙØ§Ø±Ø³Û</a> </li> <li class="section-language"> <a class="" href="full/fr#CD002190-abs-0014">FranÃ§ais</a> </li> <li class="section-language"> <a class="" href="full/hr#CD002190-abs-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD002190-abs-0009">æ¥æ¬èª</a> </li> <li class="section-language"> <a class="" href="full/ko#CD002190-abs-0005">íêµ­ì´</a> </li> <li class="section-language"> <a class="" href="full/ms#CD002190-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD002190-abs-0015">Polski</a> </li> <li class="section-language"> <a class="" href="full/th#CD002190-abs-0007">à¸ à¸²à¸©à¸²à¹à¸à¸¢</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD002190-abs-0003">ç¹é«ä¸­æ</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD002190-abs-0002" lang="en"> <h3>Vaccines for preventing the common cold</h3> <p><b>Review question</b> </p> <p>Can vaccines help prevent the common cold?</p> <p><b>Background</b> </p> <p>The common cold is mainly caused by a viral infection of the upper respiratory tract. People with the common cold feel unwell, have a runny nose, nasal congestion, sneezing, cough with or without sore throat, and have slightly elevated temperatures. However, people usually recover when their immune system controls the impact of the viral infection. Treatment for this condition is aimed at relieving symptoms. Globally, the common cold causes widespread illness and large economic loss. In the United States, economic loss due to the common cold is estimated at more than USD 40 billion per year, including millions of workdays and school days missed. In Europe, the total cost per episode may be up to EUR 1102. There is also a large expenditure on inappropriate antimicrobial prescriptions. It has been difficult to manufacture vaccines to prevent the common cold because it is caused by several viruses. The effect of vaccines for preventing the common cold in healthy people is still unknown. </p> <p><b>Search date</b> </p> <p>The evidence is current to 26 April 2022.</p> <p><b>Study characteristics</b> </p> <p>We did not identify any new trials for inclusion in this update. This review includes one previously identified randomised controlled trial (a type of study where participants are randomly assigned to one of two or more treatment groups) performed in 1965. This study involved 2307 young, healthy military men at a training facility in the United States Navy, and evaluated the effects of a live attenuated (weakened) adenovirus vaccine, an inactivated type 4, and an inactivated type 4 and 7 vaccines compared to a placebo (fake vaccine). </p> <p><b>Study funding sources</b> </p> <p>The included trial was funded by a government institution.</p> <p><b>Key results</b> </p> <p>There were no differences in the frequency of occurrence of the common cold between those who received aÂ live attenuated adenovirus vaccine compared to those who received a placebo. There were no differences between groups in adverse events. However, as the trial participants were not representative of the general population and there were flaws in the study design, our confidence in the results is very low. Further research is needed to find out if vaccines can prevent the common cold, as the current evidence does not support the use of the adenovirus vaccine to prevent the common cold in healthy people. </p> <p><b>Certainty of the evidence</b> </p> <p>We assessed the certainty of the evidence as very low due to high risk of bias; because the study population was only young men; and due to the small number of people included in the study and low numbers of colds. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD002190-sec-0061" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD002190-sec-0061"></div> <h3 class="title" id="CD002190-sec-0062">Implications for practice</h3> <section id="CD002190-sec-0062"> <p>This Cochrane Review update found very limited evidence on the effects of vaccines for the common cold in healthy people. We included only one randomised controlled trial, which did not report differences between comparison groups. Our findings were based on only one trial with very lowâcertainty evidence with an unclear risk of bias, indirectness, and imprecision.Â <a href="./references#CD002190-bbs2-0001" title="GriffinJP , GreenbergBH . Live and inactivated adenovirus vaccines. Clinical evaluation of efficacy in prevention of acute respiratory disease. Archives of Internal Medicine1970;125(6):981-6. [PMID: 4378136]">Griffin 1970</a>Â involved 2307 participants and assessed adenovirus vaccines compared with placebo, and showed that there may be no difference between the adenovirus vaccine and placebo in reducing the incidence of the common cold.Â  </p> </section> <h3 class="title" id="CD002190-sec-0063">Implications for research</h3> <section id="CD002190-sec-0063"> <p>This 2022 update highlights the need for wellâdesigned, highâquality randomised clinical trials to assess the effectiveness and safety of vaccines to prevent the common cold in healthy people. Future trials should include outcomes such as common cold incidence, vaccine safety, mortality, and adverse events related to vaccine administration. Inert placebo use would also be beneficial to avoid dampening adverse events following immunisation. Future trials should be conducted by independent researchers and reported according to CONSORT guidelines (<a href="./references#CD002190-bbs2-0232" title="MoherD , HopewellS , SchulzKF , MontoriV , GÃ¸tzschePC , DevereauxPJ , et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. International Journal of Surgery2012;10(1):28-55. [DOI: 10.1016/j.ijsu.2011.10.001] [PMID: 22036893]">Moher 2012</a>;Â <a href="./references#CD002190-bbs2-0241" title="Methodology Committee of the Patient-Centered Outcomes Research Institute (PCORI). Methodological standards and patient-centeredness in comparative effectiveness research: the PCORI perspective. JAMA2012;307(15):1636-40. [PMID: 22511692]">PCORI 2012</a>), and should adhere to the Foundation of PatientâCentered Outcomes Research recommendations (<a href="./references#CD002190-bbs2-0191" title="GabrielSE , NormandSL . Getting the methods right - the foundation of patient-centered outcomes research. New England Journal of Medicine2012;367(9):787-90. [DOI: 10.1056/NEJMp1207437]">Gabriel 2012</a>). </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD002190-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD002190-sec-0008"></div> <div class="table" id="CD002190-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span>Â <span class="table-title">Virus vaccines compared to placebo for preventing the common cold in healthy people</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Virus vaccines compared to placebo for preventing the common cold in healthy people</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> young, healthy men in a military facility<br/><b>Settings:</b> navy training centre<br/><b>Intervention:</b> adenovirus vaccines (live, inactivated type 4, and inactivated type 4 and 7)<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Virus vaccines for preventing the common cold</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Incidence of the common cold</b> </p> <p>Number of participants with common cold by group<br/>Followâup: mean 9 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.95Â </b><br/>(0.45 to 2.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2307<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>ââââ<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Â </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>12 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>11 per 1000</b><br/>(5 to 24) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vaccine safety</b> </p> <p>Followâup: mean 9 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>The study reported that there were no differences between groups in vaccineârelated adverse events. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2307<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Â </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality: vaccine related and all cause</b> â not reported </p> <p>Followâup: mean 9 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>See comments</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The included study did not report this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.Â  </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to unclear risk of bias.<br/><sup>b</sup>Downgraded one level due to indirectness as the study population is only young men.<br/><sup>c</sup>Downgraded one level due to imprecision as confidence intervals are wide, and the number of events is low. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD002190-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD002190-sec-0009"></div> <p>Â </p> <section id="CD002190-sec-0010"> <h3 class="title" id="CD002190-sec-0010">Description of the condition</h3> <p>Although there is no standard definition for the common cold (seeÂ <a href="./appendices#CD002190-sec-0067">Appendix 1</a>), it is generally defined as a spontaneously remitting infection of the upper respiratory tract (URT), characterised by a runny nose, nasal congestion, and sneezing. Other symptoms associated with the common cold include cough, malaise, sore throat, and fever (usually &lt; 100 ÂºF/37.8 ÂºC) (<a href="./references#CD002190-bbs2-0186" title="EcclesR . Mechanisms of symptoms of common cold and flu. Common Cold2009;10:23â45. [DOI: 10.1007/978-3-7643-9912-2_2] [PMID: PMC7122998]">Eccles 2009</a>). A temperature of 100 ÂºF/37.8 ÂºC or higher for three to four days is typically associated with influenza and other respiratory diseases (seeÂ <a href="./appendices#CD002190-sec-0068">Appendix 2</a>) (<a href="./references#CD002190-bbs2-0182" title="Division of Disease Control and Prevention, Utah Department of Health. Difference between cold and flu symptoms. health.utah.gov/epi/diseases/flu/ColdvsFlu.pdf (accessed 10 October 2021).">DDCP 2010</a>). Despite the fact that the common cold is not considered to be a deadly disease, bacterial complications can lead to high morbidity and mortality (<a href="./references#CD002190-bbs2-0192" title="Giraud-GatineauA , ColsonP , JimenoMT , ZandottiC , NinoveL , BoschiC , et al. Comparison of mortality associated with respiratory viral infections between December 2019 and March 2020 with that of the previous year in Southeastern France. International Society for Infectious Diseases2020;96:154-6. [DOI: 10.1016/j.ijid.2020.05.001] [PMID: 32389848]">GiraudâGatineau 2020</a>;Â <a href="./references#CD002190-bbs2-0269" title="VeigaA , MartinsLG , RiedigerI , MazettoA , DeburM , GregianiniTS . More than just a common cold: endemic coronaviruses OC43, HKU1, NL63, and 229E associated with severe acute respiratory infection and fatality cases among healthy adults. Journal of Medical Virology2021;93(2):1002-7. [DOI: 10.1002/jmv.26362] [PMID: 32720706]">Veiga 2021</a>).Â  </p> <p>The common cold is a disease of diverse aetiologyÂ (seeÂ <a href="./appendices#CD002190-sec-0069">Appendix 3</a>) (<a href="./references#CD002190-bbs2-0203" title="HeikkinenT , JarvinenA . The common cold. Lancet2003;361(9351):51-9. [PMID: 12517470]">Heikkinen 2003</a>). Premature babies, children, the elderly, and other populations with comorbidities such as chronic lung diseases (chronic obstructive pulmonary disease), congenital heart disease, and asthma are more prone to viral infections that cause the common cold, including respiratory syncytial virus (RSV), human rhinovirus (HRV), parainfluenza, coronavirus, and adenovirus (nonâpolio) (<a href="./references#CD002190-bbs2-0212" title="JohnstonNW , OlssonM , EdsbÃ¤ckerS , Gerhardsson de VerdierM , GustafsonP , McCraeC , et al. Colds as predictors of the onset and severity of COPD exacerbations. International Journal of Chronic Obstructive Pulmonary Disease2017;12:839-48. [DOI: 10.2147/COPD.S127146] [PMID: 28331305]">Johnston 2017</a>;Â <a href="./references#CD002190-bbs2-0224" title="LuC , NorbÃ¤ckD , ZhangY , LiB , ZhaoZ , HuangC , et al. Common cold among young adults in China without a history of asthma or allergic rhinitis - associations with warmer climate zone, dampness and mould at home, and outdoor PM10Â and PM2.5. Science of the Total Environment2020;749:141580. [DOI: 10.1016/j.scitotenv.2020.141580] [PMID: 32841860]">Lu 2020</a>;Â <a href="./references#CD002190-bbs2-0253" title="RubnerFJ , JacksonDJ , EvansMD , GangnonRE , TislerCJ , PappasTE , et al. Early life rhinovirus wheezing, allergic sensitization, and asthma risk at adolescence. Journal of Allergy and Clinical Immunology2017;139(2):501-7. [DOI: 10.1016/j.jaci.2016.03.049] [PMID: 27312820]">Rubner 2017</a>;Â <a href="./references#CD002190-bbs2-0256" title="ShibataM , IwaneT , HiguchiR , SuwaK , NakajimaK . Potential common factors associated with predisposition to common cold in middle-aged and elderly Japanese: a community-based cross-sectional study. Medicine (Baltimore)2018;97(20):e10729. [DOI: 10.1097/MD.0000000000010729] [PMID: 29768343]">Shibata 2018</a>). Additionally, in humans, coronavirus such as the HCoVâ229E, HCoVâOC43, HCoVâNL63, and HCoVâHKU1 strains are responsible for URT infections (URTI) associated with the common cold (<a href="./references#CD002190-bbs2-0275" title="ZumlaA , ChanJF , AzharEI , HuiDS , YuenKY . Coronaviruses - drug discovery and therapeutic options. Nature Reviews Drug Discovery2016;15(5):327-47. [DOI: 10.1038/nrd.2015.37] [PMID: 26868298]">Zumla 2016</a>). It has been shown that 1% to 10% of the population is infected with the HCoVâNL63 coronavirus annually (<a href="./references#CD002190-bbs2-0261" title="SzelazekB , KabalaW , KusK , ZdzalikM , Twarda-ClapaA , GolikP , et al. Structural characterization of human coronavirus NL63 N protein. Journal of Virology2017;91(11):e02503-16. [DOI: 10.1128/JVI.02503-16] [PMID: 28331093]">Szelazek 2017</a>). Even the infectious agent SARSâCoVâ2 can be associated with the common cold (<a href="./references#CD002190-bbs2-0274" title="ZimmermannP , CurtisN . Coronavirus infections in children including COVID-19: an overview of the epidemiology, clinical features, diagnosis, treatment and prevention options in children. Pediatric Infectious Disease Journal2020;39(5):355-68. [DOI: 10.1097/INF.0000000000002660] [PMID: 32310621]">Zimmermann 2020</a>). The transmission of the common cold occurs through aerosols, direct contact with infected nasal secretions, orÂ fomites (<a href="./references#CD002190-bbs2-0183" title="DeGeorgeKC , RingDJ , DalrympleSN . Treatment of the common cold. American Family Physician2019;100(5):281-9. [PMID: 31478634]">DeGeorge 2019</a>;Â <a href="./references#CD002190-bbs2-0218" title="L'HuillierAG , TapparelC , TurinL , Boquete-SuterP , ThomasY , KaiserL . Survival of rhinoviruses on human fingers. Clinical Microbiology and Infection2015;21(4):381-5. [DOI: 10.1016/j.cmi.2014.12.002] [PMID: 25614158]">L'Huillier 2015</a>;Â <a href="./references#CD002190-bbs2-0249" title="ReynoldsKA , BeamerPI , PlotkinKR , SifuentesLY , KoenigDW , GerbaCP . The healthy workplace project: reduced viral exposure in an office setting. Archives of Environmental &amp; Occupational Health2016;71(3):157-62. [DOI: 10.1080/19338244.2015.1058234] [PMID: 26066784]">Reynolds 2016</a>); the primary factors that contribute to the spread of this disease include poor hand hygiene, overcrowding, and interactions in places such as schools, dayâcare centres, and between households (<a href="./references#CD002190-bbs2-0168" title="AdlerFR , StockmannC , AmpofoK , PaviaAT , ByingtonCL . Transmission of rhinovirus in the Utah BIG-LoVE families: consequences of age and household structure. PLOS ONE2018;13(7):e0199388. [DOI: 10.1371/journal.pone.0199388] [PMID: 30044794]">Adler 2018</a>;Â <a href="./references#CD002190-bbs2-0170" title="AlexandrinoAS , SantosR , MeloC , BastosJM . Risk factors for respiratory infections among children attending day care centres. Family Practice2016;33(2):161-6. [DOI: 10.1093/fampra/cmw002] [PMID: 26884444]">Alexandrino 2016</a>).Â  </p> <p>The common cold is one of the most frequent illnesses experienced by humans.Â Children may experience up to 11 URTIs annually (<a href="./references#CD002190-bbs2-0219" title="LambertSB , AllenKM , DruceJD , BirchCJ , MackayIM , CarlinJB , et al. Community epidemiology of human metapneumovirus, human coronavirus NL63, and other respiratory viruses in healthy preschool-aged children using parent-collected specimens. Pediatrics2007;120(4):e929-37. [DOI: 10.1542/peds.2006-3703] [PMID: 17875651]">Lambert 2007</a>;Â <a href="./references#CD002190-bbs2-0262" title="TangJ , ChenJ , HeT , JiangZ , ZhouJ , HuB , et al. Diversity of upper respiratory tract infections and prevalence of Streptococcus pneumoniae colonization among patients with fever and flu-like symptoms. BMC Infectious Diseases2019;19(1):24. [DOI: 10.1186/s12879-018-3662-z] [PMID: 30616564]">Tang 2019</a>), whilst adults experience an average of two episodes per year (<a href="./references#CD002190-bbs2-0267" title="TomitaK , SanoH , IwanagaT , IshiharaK , IchinoseM , KawaseI , et al. Association between episodes of upper respiratory infection and exacerbations in adult patients with asthma. Journal of Asthma2012;49(3):253-9. [DOI: 10.3109/02770903.2012.661009] [PMID: 22376075]">Tomita 2012</a>;Â <a href="./references#CD002190-bbs2-0270" title="VisseauxB , BurdetC , VoiriotG , LescureFX , ChougarT , BrugiÃ¨reO , et al. Prevalence of respiratory viruses among adults, by season, age, respiratory tract region and type of medical unit in Paris, France, from 2011 to 2016. PLOS ONE2017;12(7):e0180888. [DOI: 10.1371/journal.pone.0180888] [PMID: 28708843]">Visseaux 2017</a>). For instance, HRV is responsible for 50% to 80% of common colds, and it is an important cause of morbidity, reduced productivity, and inappropriate use of antibiotics (<a href="./references#CD002190-bbs2-0215" title="KardosP , MalekFA . Common cold - an umbrella term for acute infections of nose, throat, larynx and bronchi. Pneumologie2017;71(4):221-6. [DOI: 10.1055/s-0042-116112] [PMID: 27912214]">Kardos 2017</a>;Â <a href="./references#CD002190-bbs2-0271" title="WarnerSM , WiehlerS , MichiAN , ProudD . Rhinovirus replication and innate immunity in highly differentiated human airway epithelial cells. Respiratory Research2019;20(1):150. [DOI: 10.1186/s12931-019-1120-0] [PMID: 31299975]">Warner 2019</a>). Although there are few studies on the socioeconomic costs of the common cold, and most existing studies are problematic in terms of methodology (e.g. recall bias) for mainly being crossâsectional studies on selfâreported surveys performed in a small or specific population, the impact on school and work absenteeism caused by common cold and the economic burden it causes cannot be overlooked (<a href="./references#CD002190-bbs2-0185" title="DicpinigaitisPV , EcclesR , BlaissMS , WingertzahnMA . Impact of cough and common cold on productivity, absenteeism, and daily life in the United States: ACHOO Survey. Current Medical Research and Opinion2015;31(8):1519-25. [DOI: 10.1185/03007995.2015.1062355] [PMID: 26073933]">Dicpinigaitis 2015</a>;Â <a href="./references#CD002190-bbs2-0208" title="JaumeF , Valls-MateusM , MullolJ . Common cold and acute rhinosinusitis: up-to-date management in 2020. Current Allergy and Asthma Reports2020;20(7):28. [DOI: 10.1007/s11882-020-00917-5] [PMID: 32495003]">Jaume 2020</a>;Â <a href="./references#CD002190-bbs2-0209" title="JaumeF , QuintÃ³LL , AlobidI , MullolJ . Direct costs of acute rhinosinusitis in Spain - a prospective and observational study (PROSINUS). Journal of Investigational Allergology and Clinical Immunology2021;31(6):481-8. [DOI: 10.18176/jiaci.0525] [PMID: 32694096]">Jaume 2021</a>). In the United States, economic loss due to the common cold is estimated at more than USD 40 billion per year, including an estimate of 70 million workdays missed by employees suffering from a cold, 189 million school days missed by children, and 126 million work days missed by parents caring for children with a cold (<a href="./references#CD002190-bbs2-0215" title="KardosP , MalekFA . Common cold - an umbrella term for acute infections of nose, throat, larynx and bronchi. Pneumologie2017;71(4):221-6. [DOI: 10.1055/s-0042-116112] [PMID: 27912214]">Kardos 2017</a>), all of which have an impact on productivity (<a href="./references#CD002190-bbs2-0185" title="DicpinigaitisPV , EcclesR , BlaissMS , WingertzahnMA . Impact of cough and common cold on productivity, absenteeism, and daily life in the United States: ACHOO Survey. Current Medical Research and Opinion2015;31(8):1519-25. [DOI: 10.1185/03007995.2015.1062355] [PMID: 26073933]">Dicpinigaitis 2015</a>). In Europe, the total cost per episode may be up to EUR 1102, of which 75% are indirect costs (<a href="./references#CD002190-bbs2-0258" title="StjÃ¤rneP , OdebÃ¤ckP , StÃ¤llbergB , LundbergJ , OlssonP . High costs and burden of illness in acute rhinosinusitis: real-life treatment patterns and outcomes in Swedish primary care. Primary Care Respiratory Journal2012;21(2):174-9. [DOI: 10.4104/pcrj.2012.00011] [PMID: 22349918]">StjÃ¤rne 2012</a>). Additionally, there is a large expenditure due to inappropriate antimicrobial prescription and use for URTI (<a href="./references#CD002190-bbs2-0268" title="TsuzukiS , KimuraY , IshikaneM , KusamaY , OhmagariN . Cost of inappropriate antimicrobial use for upper respiratory infection in Japan. BMC Health Services Research2020;20(1):153. [DOI: 10.1186/s12913-020-5021-1] [PMID: 32111202]">Tsuzuki 2020</a>).Â  </p> </section> <section id="CD002190-sec-0011"> <h3 class="title" id="CD002190-sec-0011">Description of the intervention</h3> <p>There is no specific treatment for the common cold. Treatment is focused on easing the symptoms.Â Prevention is therefore essential to stop the spread of viruses that cause the common cold. In terms of preventive measures, studies have shown that simple measures such as handwashing and maintaining physical distance are relevant to all respiratory infections, but difficult to apply or enforce because, as time passes, motivation and compliance may decrease (<a href="./references#CD002190-bbs2-0171" title="AllanGM , ArrollB . Prevention and treatment of the common cold: making sense of the evidence. Canadian Medical Association Journal2014;186(3):190-9. [DOI: 10.1503/cmaj.121442] [PMID: 24468694]">Allan 2014</a>;Â <a href="./references#CD002190-bbs2-0211" title="JeffersonT , Del MarCB , DooleyL , FerroniE , Al-AnsaryLA , BawazeerGA , et al. Physical interventions to interrupt or reduce the spread of respiratory viruses. Cochrane Database of Systematic Reviews2020, Issue 11. Art. No: CD006207. [DOI: 10.1002/14651858.CD006207.pub5]">Jefferson 2020</a>).Â Consequently, another method of prevention is vaccination. The development of vaccines for the common cold has been challenging because of the aetiological diversity of the diseaseÂ and the antigenic variability of the common cold viruses (<a href="./references#CD002190-bbs2-0193" title="GlanvilleN , McLeanGR , GuyB , LecouturierV , BerryC , GirerdY , et al. Cross-serotype immunity induced by immunization with a conserved rhinovirus capsid protein. PLOS Pathogens2013;9(9):e1003669. [DOI: 10.1371/journal.ppat.1003669] [PMID: 24086140]">Glanville 2013</a>;Â <a href="./references#CD002190-bbs2-0266" title="ToKK , YipCC , YuenKY . Rhinovirus - from bench to bedside. Journal of the Formosan Medical Association2017;116(7):496-504. [DOI: 10.1016/j.jfma.2017.04.009] [PMID: 28495415]">To 2017</a>). The case of HRV remains a challenge for the public health and scientific communities due to technical, logistical, and fundamental biological difficulties (<a href="./references#CD002190-bbs2-0259" title="StobartCC , NosekJM , MooreML . Rhinovirus biology, antigenic diversity, and advancements in the design of a human rhinovirus vaccine. Frontiers in Microbiology2017;5(8):2412. [DOI: 10.3389/fmicb.2017.02412] [PMID: 29259600]">Stobart 2017</a>). Unlike several human viruses, HRV vaccine must be able to elicit protective neutralising antibodies to potentially over 150 serologically distinct types spanning three different species (<a href="./references#CD002190-bbs2-0246" title="RenL , YangD , RenX , LiM , MuX , WangQ , et al. Genotyping of human rhinovirus in adult patients with acute respiratory infections identified predominant infections of genotype A21. Scientific Reports2017;7:41601. [DOI: 10.1038/srep41601] [PMID: 28128353]">Ren 2017</a>;Â <a href="./references#CD002190-bbs2-0259" title="StobartCC , NosekJM , MooreML . Rhinovirus biology, antigenic diversity, and advancements in the design of a human rhinovirus vaccine. Frontiers in Microbiology2017;5(8):2412. [DOI: 10.3389/fmicb.2017.02412] [PMID: 29259600]">Stobart 2017</a>). For this reason, it is difficult to develop a vaccine that provides full protection (<a href="./references#CD002190-bbs2-0257" title="StepanovaE , Isakova-SivakI , RudenkoL . Overview of human rhinovirus immunogenic epitopes for rational vaccine design. Expert Review of Vaccines2019;18(9):877-80. [DOI: 10.1080/14760584.2019.1657014] [PMID: 31416365]">Stepanova 2019</a>). Despite these challenges, recent attempts using rhinovirusâderived VP1, a surface protein that is critically involved in the infection of respiratory cells, has demonstrated that with enough exposure and recombinant VP1 as an immunogen, crossâserotype reactive antibodies can be generated (<a href="./references#CD002190-bbs2-0187" title="EdlmayrJ , NiespodzianaK , Popow-KrauppT , KrzyzanekV , Focke-TejklM , BlaasD , et al. Antibodies induced with recombinant VP1 from human rhinovirus exhibit cross-neutralisation. European Respiratory Journal2011;37(1):44-52. [DOI: 10.1183/09031936.00149109] [PMID: 20530036]">Edlmayr 2011</a>;Â <a href="./references#CD002190-bbs2-0229" title="McLeanGR , WaltonRP , ShettyS , PeelTJ , PaktiawalN , KebadzeT , et al. Rhinovirus infections and immunisation induce cross-serotype reactive antibodies to VP1. Antiviral Research2012;95(3):193-201. [DOI: 10.1016/j.antiviral.2012.06.006] [PMID: 22742898]">McLean 2012</a>). The future of vaccine development for the common cold seems promising, considering that studies on virus genotyping such as HRV genotype are being published more frequently (<a href="./references#CD002190-bbs2-0225" title="LukaMM , KamauE , AdemaI , MunywokiPK , OtienoGP , GicheruE , et al. Molecular epidemiology of human rhinovirus from 1-year surveillance within a school setting in rural coastal Kenya. Open Forum Infectious Diseases2020;7(10):ofaa385. [DOI: 10.1093/ofid/ofaa385] [PMID: 33094115]">Luka 2020</a>;Â <a href="./references#CD002190-bbs2-0246" title="RenL , YangD , RenX , LiM , MuX , WangQ , et al. Genotyping of human rhinovirus in adult patients with acute respiratory infections identified predominant infections of genotype A21. Scientific Reports2017;7:41601. [DOI: 10.1038/srep41601] [PMID: 28128353]">Ren 2017</a>), and there is a rapid technological development of vaccines that include microâ/nanoparticle material and recombinant technologies (<a href="./references#CD002190-bbs2-0240" title="PapadopoulosNG , MegremisS , KitsioulisNA , VangelatouO , WestP , XepapadakiP . Promising approaches for the treatment and prevention of viral respiratory illnesses. Journal of Allergy and Clinical Immunology2017;140(4):921-32. [DOI: 10.1016/j.jaci.2017.07.001] [PMID: 28739285]">Papadopoulos 2017</a>). </p> <p>Adenovirus is a recognised pathogen of the URT (<a href="./references#CD002190-bbs2-0177" title="BiserniGB , DondiA , MasettiR , BandiniJ , DormiA , ContiF , et al. Immune response against adenovirus in acute upper respiratory tract infections in immunocompetent children. Vaccines (Basel)2020;8(4):602. [DOI: 10.3390/vaccines8040602] [PMID: 33066100]">Biserni 2020</a>).Â Adenovirus serotype 4 (Ad4) and serotype 7 (Ad7) vaccines were used during immunisation programmes beginning in 1971.Â Unfortunately, their interruption triggered the reâemergence of adenovirusâproduced diseases in crowded locations.Â An example of this reappearance was documented in US military training sites, where Ad4 accounted for 98% of all diagnosesÂ (<a href="./references#CD002190-bbs2-0254" title="RussellKL , HawksworthAW , RyanMA , StricklerJ , IrvineM , HansenCJ , et al. Vaccine-preventable adenoviral respiratory illness in US military recruits, 1999-2004. Vaccine2006;24(15):2835-42. [PMID: 16480793]">Russell 2006</a>).Â The development and deployment of AdVâ4 and AdVâ7 vaccines is essential in controlling AdVâ4â and AdVâ7ârelated URTI (<a href="./references#CD002190-bbs2-0180" title="CollinsND , AdhikariA , YangY , KuschnerRA , KarasavvasN , BinnLN , et al. Live oral adenovirus type 4 and type 7 vaccine induces durable antibody response. Vaccines (Basel)2020;8(3):411. [DOI: 10.3390/vaccines8030411] [PMID: 32718082]">Collins 2020</a>). Adenoviral vaccines delivered orally have been used for decades to prevent respiratory illnesses. New studies have concluded that these vaccines are safe and have brought about a large immune response in the studied populations. For instance, a study examining the duration of the neutralising antibody response generated from a live oral AdVâ4 and AdVâ7 vaccine showed that, regardless of preâvaccination serostatus, participants developed a significant antibody response which persisted for at least six years after vaccination (<a href="./references#CD002190-bbs2-0180" title="CollinsND , AdhikariA , YangY , KuschnerRA , KarasavvasN , BinnLN , et al. Live oral adenovirus type 4 and type 7 vaccine induces durable antibody response. Vaccines (Basel)2020;8(3):411. [DOI: 10.3390/vaccines8030411] [PMID: 32718082]">Collins 2020</a>). </p> <p>RSV is an important cause of respiratory infection in older adults, and almost all children have been infected with RSV by the age of two; due to incomplete and shortâlived natural immunity, repeated RSV infections occur throughout life (<a href="./references#CD002190-bbs2-0150" title="WilliamsK , BastianAR , FeldmanRA , OmoruyiE , dePaepeE , HendriksJ , et al. Phase 1 safety and immunogenicity study of a respiratory syncytial virus vaccine with an adenovirus 26 vector encoding prefusion F (Ad26.RSV.preF) in adults aged â¥ 60 years. Journal of Infectious Diseases2020;222(6):979-88. [DOI: 10.1093/infdis/jiaa193] [PMID: 32320465]">Williams 2020</a>). The development of an RSV vaccine has been difficult due to antigenic variability, especially in proteins F and G. However, a firstâinâhuman phase 1 trial has been reported to evaluate the safety and immunogenicity of an experimental RSV vaccine of Ad26.RSV.preF (a replicationâincompetent adenovirusâ26 vector encoding the F protein), which is administered intramuscularly 12 months apart in healthy adults aged â¥ 60 years old (<a href="./references#CD002190-bbs2-0150" title="WilliamsK , BastianAR , FeldmanRA , OmoruyiE , dePaepeE , HendriksJ , et al. Phase 1 safety and immunogenicity study of a respiratory syncytial virus vaccine with an adenovirus 26 vector encoding prefusion F (Ad26.RSV.preF) in adults aged â¥ 60 years. Journal of Infectious Diseases2020;222(6):979-88. [DOI: 10.1093/infdis/jiaa193] [PMID: 32320465]">Williams 2020</a>). There have also been concerns of enhanced respiratory disease (ERD) after vaccination with the formalinâinactivated RSV vaccines in the 1960s, in which patients showed Xâray evidence of severe pneumonia and bronchiolitis, in addition to immunopotentiation induced by a T helper (Th)â2 and Th17 T cell responses with the enrolment of T cells, neutrophils, and eosinophils causing inflammation and tissue damage (<a href="./references#CD002190-bbs2-0248" title="Rey-JuradoE , KalergisAM . Immunological features of respiratory syncytial virus-caused pneumonia - implications for vaccine design. International Journal of Molecular Sciences2017;18(3):556. [DOI: 10.3390/ijms18030556]">ReyâJurado 2017</a>). Current vaccine candidates, especially those designed for infants and children, whose immune systems are still immature, must therefore be safe and avoid these immunologic features of ERD (<a href="./references#CD002190-bbs2-0228" title="MazurNI , HigginsD , NunesMC , MeleroJA , LangedijkAC , HorsleyN , et al. The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates. Lancet Infectious Diseases2018;18(10):e295-311. [DOI: 10.1016/S1473-3099(18)30292-5] [PMID: 29914800]">Mazur 2018</a>). </p> <p>One RSV immunisation approach is the development of a vaccine for pregnant women, since it has been demonstrated that RSVâneutralising antibodies are transferred from the pregnant woman to the foetus through the placenta (<a href="./references#CD002190-bbs2-0179" title="ChuHY , SteinhoffMC , MagaretA , ZamanK , RoyE , LangdonG , et al. Respiratory syncytial virus transplacental antibody transfer and kinetics in mother-infant pairs in Bangladesh. Journal of Infectious Diseases2014;210(10):1582-9. [DOI: 10.1093/infdis/jiu316] [PMID: 24903663]">Chu 2014</a>). A clinical trial in which healthy pregnant women received either an intramuscular dose of RSV fusion (F) protein nanoparticle vaccine or placebo, showed that during the first 90 days of life, infants with RSV had a significantly lower number of respiratory tract infections (1.5%) compared to the placebo group (2.4%). However, to tag the vaccine as successful in terms of efficacy, its possible benefits with respect to other endpoint events have to be demonstrated (<a href="./references#CD002190-bbs2-0065" title="MadhiSA , PolackFP , PiedraPA , MunozFM , TrenholmeAA , SimÃµesE , et al. Respiratory syncytial virus vaccination during pregnancy and effects in infants. New England Journal of Medicine2020;383(5):426-39. [DOI: 10.1056/NEJMoa1908380] [PMID: 32726529]">Madhi 2020</a>). Another phase II clinical trial evaluated the tolerability and safety of RSV fusion (F) protein nanoparticle vaccine compared to placebo in 50 healthy thirdâtrimester pregnant women and their infants (<a href="./references#CD002190-bbs2-0234" title="MuÅozFM , SwamyGK , HickmanSP , AgrawalS , PiedraPA , GlennGM , et al. Safety and immunogenicity of a respiratory syncytial virus fusion (F) protein nanoparticle vaccine in healthy third-trimester pregnant women and their infants. Journal of Infectious Diseases2019;220(11):1802-15. [DOI: 10.1093/infdis/jiz390] [PMID: 31402384]">MuÅoz 2019</a>). The trial demonstrated that the vaccine was well tolerated with no differences on safety outcomes other than expected shortâterm reactogenicity in women who received the active vaccine. In addition, transplacental antibody transfer ranged between 90% and 120% across assays for infants of the vaccinated group of women (<a href="./references#CD002190-bbs2-0234" title="MuÅozFM , SwamyGK , HickmanSP , AgrawalS , PiedraPA , GlennGM , et al. Safety and immunogenicity of a respiratory syncytial virus fusion (F) protein nanoparticle vaccine in healthy third-trimester pregnant women and their infants. Journal of Infectious Diseases2019;220(11):1802-15. [DOI: 10.1093/infdis/jiz390] [PMID: 31402384]">MuÅoz 2019</a>). </p> <p>Regarding parainfluenza, there is still no approved vaccine available. However, the intranasal administration of two doses of aÂ liveâattenuated human parainfluenza virus type 3 HPIV3âcp45 vaccine seems promising, as it has been shown to be well tolerated and immunogenic in seronegative children over six months of age (<a href="./references#CD002190-bbs2-0216" title="KarronRA , CaseyR , ThumarB , SurmanS , MurphyBR , CollinsPL , et al. The cDNA-derived investigational human parainfluenza virus type 3 vaccine rcp45 is well tolerated, infectious, and immunogenic in infants and young children. Pediatric Infectious Disease Journal2011;30(10):e186-91. [DOI: 10.1097/INF.0b013e31822ea24f] [PMID: 21829138]">Karron 2011</a>).Â  </p> </section> <section id="CD002190-sec-0012"> <h3 class="title" id="CD002190-sec-0012">How the intervention might work</h3> <p>Vaccines work by inducing an immune response, such as an antibody response that interferes with a pathogenic invasion and prevents their adherence to epithelial cells through opsonisation, phagocytosis, and other mechanisms (<a href="./references#CD002190-bbs2-0242" title="PichicheroME . Booster vaccinations: can immunologic memory outpace disease pathogenesis?Pediatrics2009;124(6):1633-41. [MEDLINE: 19933727]">Pichichero 2009</a>;Â <a href="./references#CD002190-bbs2-0273" title="WoodenSL , KoffWC . The human vaccines project: towards a comprehensive understanding of the human immune response to immunization. Human Vaccines &amp; Immunotherapeutics2018;14(9):2214-6. [DOI: 10.1080/21645515.2018.1476813] [PMID: 29847214]">Wooden 2018</a>). A correlate of protection to a pathogen is a measurable sign that a person is immune after vaccination, and can either be absolute or relative (<a href="./references#CD002190-bbs2-0244" title="PlotkinSA . Updates on immunologic correlates of vaccine-induced protection. Vaccine2020;38(9):2250-7. [DOI: 10.1016/j.vaccine.2019.10.046] [PMID: 31767462]">Plotkin 2020</a>). There may also be more than one correlate of protection for a disease, known as 'coâcorrelates' (<a href="./references#CD002190-bbs2-0244" title="PlotkinSA . Updates on immunologic correlates of vaccine-induced protection. Vaccine2020;38(9):2250-7. [DOI: 10.1016/j.vaccine.2019.10.046] [PMID: 31767462]">Plotkin 2020</a>). The immune memory is a critical correlate (effector memory for shortâincubation and central memory for longâincubation diseases), and cellâmediated immunity can operate as a correlate or coâcorrelate of protection against a disease (<a href="./references#CD002190-bbs2-0243" title="PlotkinSA . Correlates of protection induced by vaccination. Clinical and Vaccine Immunology2010;17(7):1055-65. [DOI: 10.1128/CVI.00131-10] [PMID: 20463105]">Plotkin 2010</a>). However, some vaccines only have surrogates for an unknown protective response, which are easy measurements but not functional (<a href="./references#CD002190-bbs2-0243" title="PlotkinSA . Correlates of protection induced by vaccination. Clinical and Vaccine Immunology2010;17(7):1055-65. [DOI: 10.1128/CVI.00131-10] [PMID: 20463105]">Plotkin 2010</a>). For instance, as there is no correlate of protection for the development of HRV vaccines, serum IgA is used as a surrogate marker for studies on all live attenuated HRV vaccines to demonstrate vaccine take (<a href="./references#CD002190-bbs2-0173" title="ArmahG , LewisKD , CorteseMM , ParasharUD , AnsahA , GazleyL , et al. A randomized, controlled trial of the impact of alternative dosing schedules on the immune response to human rotavirus vaccine in rural Ghanaian infants. Journal of Infectious Diseases2016;213(11):1678-85. [DOI: 10.1093/infdis/jiw023] [PMID: 26823335]">Armah 2016</a>). </p> <p>Studies suggest that vaccines that mimic natural infection and take into account the structure of pathogens seem to be effective in inducing longâterm protective immunity (<a href="./references#CD002190-bbs2-0214" title="KangSM , CompansRW . Host responses from innate to adaptive immunity after vaccination: molecular and cellular events. Molecular Cell2009;27(1):5-14. [PMID: 19214429]">Kang 2009</a>).Â Different types of vaccines against respiratory viruses already exist, but all have been focused on decreasing the incidence of lower respiratory infections. Traditionally inactivated or live attenuated viruses are used. However, there are promising approaches that use microâ/nanoparticles material and recombinant technologies that produce a broad immunogenic, reproducible, safe, and often selfâadjuvating response (<a href="./references#CD002190-bbs2-0195" title="GomesAC , MohsenM , BachmannMF . Harnessing nanoparticles for immunomodulation and vaccines. Vaccines (Basel)2017;5(1):6. [DOI: 10.3390/vaccines5010006] [PMID: 28216554]">Gomes 2017</a>;Â <a href="./references#CD002190-bbs2-0240" title="PapadopoulosNG , MegremisS , KitsioulisNA , VangelatouO , WestP , XepapadakiP . Promising approaches for the treatment and prevention of viral respiratory illnesses. Journal of Allergy and Clinical Immunology2017;140(4):921-32. [DOI: 10.1016/j.jaci.2017.07.001] [PMID: 28739285]">Papadopoulos 2017</a>). </p> </section> <section id="CD002190-sec-0013"> <h3 class="title" id="CD002190-sec-0013">Why it is important to do this review</h3> <p>Although the common cold is selfâlimiting with symptoms often lasting up to 10 days, it is the most common acute illness in industrialised countries with a very high incidence, presenting several episodes per person a year, as well as being one of the main causes of primary care consultations (<a href="./references#CD002190-bbs2-0183" title="DeGeorgeKC , RingDJ , DalrympleSN . Treatment of the common cold. American Family Physician2019;100(5):281-9. [PMID: 31478634]">DeGeorge 2019</a>;Â <a href="./references#CD002190-bbs2-0208" title="JaumeF , Valls-MateusM , MullolJ . Common cold and acute rhinosinusitis: up-to-date management in 2020. Current Allergy and Asthma Reports2020;20(7):28. [DOI: 10.1007/s11882-020-00917-5] [PMID: 32495003]">Jaume 2020</a>). Despite being generally mild, the common cold can occur with other respiratory illnesses, which can predispose susceptible individuals to potentially serious complications. Vaccines could therefore be used to reduce the prevalence of the disease around the world and decrease primary care consultations that might saturate healthcare systems. </p> <p>The socioeconomic burden from the common cold has not been fully studied, and the few studies published in this area mainly have methodological limitations. However, it has been demonstrated that the common cold can lead to work and school absenteeism as well as having an impact on productivity and healthcare costs (<a href="./references#CD002190-bbs2-0185" title="DicpinigaitisPV , EcclesR , BlaissMS , WingertzahnMA . Impact of cough and common cold on productivity, absenteeism, and daily life in the United States: ACHOO Survey. Current Medical Research and Opinion2015;31(8):1519-25. [DOI: 10.1185/03007995.2015.1062355] [PMID: 26073933]">Dicpinigaitis 2015</a>;Â <a href="./references#CD002190-bbs2-0209" title="JaumeF , QuintÃ³LL , AlobidI , MullolJ . Direct costs of acute rhinosinusitis in Spain - a prospective and observational study (PROSINUS). Journal of Investigational Allergology and Clinical Immunology2021;31(6):481-8. [DOI: 10.18176/jiaci.0525] [PMID: 32694096]">Jaume 2021</a>;Â <a href="./references#CD002190-bbs2-0215" title="KardosP , MalekFA . Common cold - an umbrella term for acute infections of nose, throat, larynx and bronchi. Pneumologie2017;71(4):221-6. [DOI: 10.1055/s-0042-116112] [PMID: 27912214]">Kardos 2017</a>), which could also be reduced by preventing the illness through vaccine use, if effective. </p> <p>Furthermore, if randomised controlled trialsÂ demonstrate that there is an effective and safe vaccine to prevent the common cold, scientists couldÂ continue researching this field. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD002190-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD002190-sec-0014"></div> <p>To assess the clinical effectiveness and safety of vaccines for preventing the common cold in healthy people. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD002190-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD002190-sec-0015"></div> <section id="CD002190-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD002190-sec-0017"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials (RCTs). We did not apply limits with respect to followâup periods. In future updates, we will consider at least 60 days of followâup. We only included RCTs that reported data about the incidence of the common cold<i>.</i> </p> </section> <section id="CD002190-sec-0018"> <h4 class="title">Types of participants</h4> <p>Healthy people aged between 6 months and 90 years.</p> </section> <section id="CD002190-sec-0019"> <h4 class="title">Types of interventions</h4> <p>Any vaccine that prevents the common cold, which protects against RSV, rhinovirus, parainfluenza, or adenovirus (nonâpolio), irrespective of dose, schedule, or administration route, versus placebo.Â We excluded trials on the prevention of influenza A and B because influenza and the common cold are two different diseases (<a href="./references#CD002190-bbs2-0210" title="JeffersonT , RivettiA , HarndenA , Di PietrantonjC , DemicheliV . Vaccines for preventing influenza in healthy children. Cochrane Database of Systematic Reviews2012, Issue 8. Art. No: CD004879. [DOI: 10.1002/14651858.CD004879.pub4]">Jefferson 2012</a>). See <a href="./appendices#CD002190-sec-0069">Appendix 3</a> for details. </p> </section> <section id="CD002190-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD002190-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD002190-list-0001"> <li> <p>Incidence of the common cold after vaccination, regardless of the causal agent determined by laboratory or clinical examination. In future updates, we will consider the incidence of the common cold as one of the primary outcomes, measured 60 days after the last dose of the vaccine. </p> </li> <li> <p>Vaccine safety, i.e. adverse events ("any untoward medical occurrence that may present during treatment with a pharmaceutical product but which does not necessarily have a causal relationship with this treatment") and adverse drug reactions ("a response to a drug which is noxious, uninitiated and which occurs at doses normally used in men for prophylaxis, diagnosis, or therapy of disease, or for the modification of physiologic functions") (<a href="./references#CD002190-bbs2-0235" title="NebekerJR , BarachP , SamoreMH . Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting. Annals of Internal Medicine2004;140(10):795-801. [PMID: 15148066]">Nebeker 2004</a>). </p> </li> <li> <p>Mortality: vaccine related and all cause.</p> </li> </ol> </p> </section> <section id="CD002190-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p>We did not consider any secondary outcomes. In future updates, we will consider mortality as a secondary outcome. </p> </section> </section> </section> <section id="CD002190-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD002190-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We updated the search strategies in the following databases:</p> <p> <ol id="CD002190-list-0002"> <li> <p>the Cochrane Central Register of Controlled Trials (CENTRAL; Issue 4, 2022), which contains the Cochrane Acute Respiratory Infections Specialised Register, searched 26 April 2022, in the Cochrane Library (<a href="./appendices#CD002190-sec-0070">Appendix 4</a>); </p> </li> <li> <p>MEDLINE via Ovid (September 2016 to 22 April 2022) (<a href="./appendices#CD002190-sec-0071">Appendix 5</a>); </p> </li> <li> <p>Embase via Elsevier (September 2016 to 22 April 2022) (<a href="./appendices#CD002190-sec-0072">Appendix 6</a>); </p> </li> <li> <p>CINAHL via EBSCO (Cumulative Index to Nursing and Allied Health Literature) (September 2016 to 22 April 2022) (<a href="./appendices#CD002190-sec-0073">Appendix 7</a>); and </p> </li> <li> <p>LILACS via BIREME (Latin American and Caribbean Health Science Information database) (September 2016 to 22 April 2022) (<a href="./appendices#CD002190-sec-0074">Appendix 8</a>). </p> </li> </ol> </p> <p>We used the Cochrane Highly Sensitive Search Strategy to identify randomised trials in MEDLINE: sensitivityâ and precisionâmaximising version (2008 revision); Ovid format (<a href="./references#CD002190-bbs2-0222" title="LefebvreC , GlanvilleJ , BriscoeS , LittlewoodA , MarshallC , Metzendorf M-I, et al. Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook/archive/v6.2.">Lefebvre 2021</a>). We adapted the search strategy to search Embase, CINAHL, and LILACS. </p> <p>We searched the following trial registries on 26 April 2022:</p> <p> <ol id="CD002190-list-0003"> <li> <p>ISRCTN registry (<a href="http://www.isrctn.com" target="_blank">www.isrctn.com</a>); </p> </li> <li> <p>ClinicalTrials.gov (<a href="https://clinicaltrials.gov/" target="_blank">clinicaltrials.gov/</a>); and </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) (<a href="http://www.who.int/ictrp/search/en/" target="_blank">www.who.int/ictrp/search/en/</a>). </p> </li> </ol> </p> <p>We did not restrict the results by language, search dates, or publication status (published, unpublished, in press, or in progress). </p> </section> <section id="CD002190-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We checked the reference lists of all relevant trials and identified reviews.Â We searched the following websites for trials on 29Â April 2022: </p> <p> <ol id="CD002190-list-0004"> <li> <p>US Food and Drug Administration (<a href="http://www.fda.gov" target="_blank">www.fda.gov</a>); </p> </li> <li> <p>European Medicines Agency (<a href="http://www.emea.europa.eu" target="_blank">www.emea.europa.eu</a>); </p> </li> <li> <p>Medicines &amp; Healthcare Products Regulatory Agency (<a href="http://www.mhra.gov.uk/index.htm" target="_blank">www.mhra.gov.uk/index.htm</a>); and </p> </li> <li> <p>Evidence in Health and Social Care (<a href="http://www.evidence.nhs.uk/" target="_blank">www.evidence.nhs.uk/</a>). </p> </li> </ol> </p> </section> </section> <section id="CD002190-sec-0026"> <h3 class="title" id="CD002190-sec-0026">Data collection and analysis</h3> <section id="CD002190-sec-0027"> <h4 class="title">Selection of studies</h4> <p>We used Cochraneâs Screen4Me workflow to help assess the search results. Screen4Me comprises three components: known assessments â a service that matches records in the search results to records that have already been screened in Cochrane Crowd and been labelled as an RCT or as nonâRCT; the RCT classifier â a machine learning model that distinguishes RCTs from nonâRCTs; and if appropriate, Cochrane Crowd â Cochraneâs citizen science platform where the Crowd help to identify and describe health evidence.Â For more information about Screen4Me and the evaluations that have been done, visit the Screen4Me web page on the <a href="https://community.cochrane.org/organizational-info/resources/resources-groups/information-specialists-portal" target="_blank">Cochrane Information Specialistâs portal</a>. More detailed information regarding evaluations of the Screen4Me components can be found in the following publications:Â <a href="./references#CD002190-bbs2-0227" title="MarshallIJ , Noel-StorrA , KuiperJ , ThomasJ , WallaceBC . Machine learning for identifying randomized controlled trials: an evaluation and practitioner's guide. Research Synthesis Methods2018;9(4):602-14. [PMID: 29314757]">Marshall 2018</a>,Â <a href="./references#CD002190-bbs2-0238" title="Noel-StorrAH , DooleyG , WisniewskiS , GlanvilleJ , ThomasJ , CoxS , et al. Cochrane centralised search service showed high sensitivity identifying randomized controlled trials: a retrospective analysis. Journal of Clinical Epidemiology2020;127:142-50. [DOI: 10.1016/j.jclinepi.2020.08.008]">NoelâStorr 2020</a>,Â <a href="./references#CD002190-bbs2-0239" title="Noel-StorrA , DooleyG , ElliottJ , SteeleE , ShemiltI , MavergamesC , et al. An evaluation of Cochrane Crowd found that crowdsourcing produced accurate results in identifying randomized trials. Journal of Clinical Epidemiology2021;133:130-9. [DOI: 10.1016/j.jclinepi.2021.01.006] [PMID: 33476769]">NoelâStorr 2021</a>,Â <a href="./references#CD002190-bbs2-0264" title="ThomasJ , McDonaldS , Noel-StorrA , ShemiltI , ElliottJ , MavergamesC , et al. Machine learning reduced workload with minimal risk of missing studies: development and evaluation of a randomized controlled trial classifier for Cochrane Reviews. Journal of Clinical Epidemiology2021;133:140-51. [DOI: 10.1016/j.jclinepi.2020.11.003]">Thomas 2021</a>.Â  </p> <p>Following Screen4Me assessment, four review authors (CM, DB, MLF, MJMZ) independently screened the titles and abstracts of studies identified as a result of the search for potential relevance. We retrieved the fullâtext reports of those studies deemed potentially relevant, and four review authors (MJMZ, CM, DB, MLF) independently screened the full texts to identify studies for inclusion in the review, and identified and recorded the reasons for exclusion of excluded studies. Any disagreements were resolved through discussion or by consulting a third review author (DSR) when needed. We identified and excluded duplicates and collated multiple reports of the same study so that each study, rather than each report, was the unit of interest in the review. We recorded the selection process in sufficient detail to complete a PRISMA flow diagram (<a href="#CD002190-fig-0001">Figure 1</a>) andÂ <a href="./references#CD002190-sec-0087" title="">Characteristics of included studies</a>Â table (<a href="./references#CD002190-bbs2-0231" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA Statement. BMJ2009;339:2535.">Moher 2009</a>). We imposed no language restrictions. </p> <div class="figure" id="CD002190-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="PRISMA flowchart" data-id="CD002190-fig-0001" src="/cdsr/doi/10.1002/14651858.CD002190.pub6/media/CDSR/CD002190/image_n/nCD002190-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA flowchart</p> </div> </div> </div> </section> <section id="CD002190-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>We used a data collection form for study characteristics and outcome data that had been piloted on at least one study in the review. Two review authors (DSR, CVG) extracted the following study characteristics from the included studies. </p> <p> <ol id="CD002190-list-0005"> <li> <p>Methods: study design, total duration of the study, details of any 'run in' period, number of study centres and location, study setting, withdrawals, and date of the study. </p> </li> <li> <p>Participants: N, mean age, age range, gender, severity of the condition, diagnostic criteria, baseline lung function, smoking history, inclusion criteria, and exclusion criteria. </p> </li> <li> <p>Interventions: intervention, comparison, concomitant medications, and excluded medications.</p> </li> <li> <p>Outcomes: primary and secondary outcomes specified and collected, and time points reported. </p> </li> <li> <p>Notes: funding for the trial, and notable conflicts of interest of trial authors.</p> </li> </ol> </p> <p>Two review authors (DSR, CVG) independently extracted outcome data from the included studies. We described in theÂ <a href="./references#CD002190-sec-0087" title="">Characteristics of included studies</a>Â table if outcome data were not reported in a usable way. Any disagreements were resolved by consensus or by involving a third review author (RH). One review author (DSR) transferred data into the Review Manager 5 file (<a href="./references#CD002190-bbs2-0247" title="Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: The Cochrane Collaboration, 2020.">Review Manager 2020</a>). We doubleâchecked that the data had been entered correctly by comparing the data presented in the systematic review with the study report. A second review author (MJMZ) spotâchecked study characteristics for accuracy against the trial report. </p> </section> <section id="CD002190-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Three review authors (DSR, CVG, RH) independently assessed risk of bias of the included studies using Cochrane's risk of bias tool RoB 1, according to the criteria in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD002190-bbs2-0206" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.">Higgins 2022</a>). Any disagreements were resolved by discussion or by involving another review author (MJMZ). We assessed the risk of bias based on the following domains. </p> <p> <ol id="CD002190-list-0006"> <li> <p>Random sequence generation.</p> </li> <li> <p>Allocation concealment.</p> </li> <li> <p>Blinding of participants and personnel.</p> </li> <li> <p>Blinding of outcome assessment.</p> </li> <li> <p>Incomplete outcome data.</p> </li> <li> <p>Selective outcome reporting.</p> </li> <li> <p>Other bias.</p> </li> </ol> </p> <p>We graded each potential source of bias as low, high, or unclear and provided quotes from the study report together with a justification for our judgement in the risk of bias table. Where necessary, we considered blinding separately for different key outcomes. </p> </section> <section id="CD002190-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>We calculated the risk ratio (RR) with 95% confidence intervals (CIs) for incidence of the common cold. We added outcome data for the included study into a data table in Review Manager 5 to calculate treatment effects (<a href="./references#CD002190-bbs2-0247" title="Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: The Cochrane Collaboration, 2020.">Review Manager 2020</a>). We used RR for dichotomous outcomes. </p> </section> <section id="CD002190-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was the participant. We collected and analysed a single measurement for each outcome from each participant. </p> </section> <section id="CD002190-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>We had planned to contact investigators or study sponsors to verify key study characteristics and to obtain missing numerical outcome data where possible (e.g. when a study was identified only as an abstract); however, this was not needed.Â  </p> </section> <section id="CD002190-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We had planned to use the IÂ² statistic to measure heterogeneity amongst trials in each analysis; however, we did not conduct a metaâanalysis because only one trial satisfied the inclusion criteria. </p> </section> <section id="CD002190-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>We did not assess publication bias using a funnel plot because we included only one trial. In future updates, we will attempt to assess whether the review is subject to publication bias by using a funnel plot if 10 or more trials are included. </p> </section> <section id="CD002190-sec-0035"> <h4 class="title">Data synthesis</h4> <p>We carried out statistical analysis using Review Manager 5 software (<a href="./references#CD002190-bbs2-0247" title="Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: The Cochrane Collaboration, 2020.">Review Manager 2020</a>). In future updates, we will summarise findings using a fixedâeffect model following the guidance in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD002190-bbs2-0206" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.">Higgins 2022</a>). </p> </section> <section id="CD002190-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We did not perform a subgroup analysis. In subsequent updates of this review, when sufficient data are available, we will carry out the following subgroup analyses: </p> <p> <ol id="CD002190-list-0007"> <li> <p>children and adults;</p> </li> <li> <p>country of study; and</p> </li> <li> <p>different responses in relation to different viral agents.</p> </li> </ol> </p> <p>We will explore sources of heterogeneity in the assessment of the primary outcomes by subgroup analyses. Additionally, due to the limited number of included studies, we do not plan on performing a metaâregression in the future. </p> </section> <section id="CD002190-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>We did not perform a sensitivity analysis. In future updates, we plan to conduct sensitivity analyses comparing the results using all trials as follows. </p> <p> <ol id="CD002190-list-0008"> <li> <p>Trials with high methodological quality (studies classified as having a 'low risk of bias' versus those identified as having a 'high risk of bias') (<a href="./references#CD002190-bbs2-0206" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.">Higgins 2022</a>). </p> </li> <li> <p>Trials that performed intentionâtoâtreat versus perâprotocol analyses.</p> </li> <li> <p>Parallel randomised clinical trials versus clusterârandomised clinical trials.</p> </li> </ol> </p> <p>We will also evaluate the risk of attrition bias, as estimated by the percentage of participants lost. We will exclude trials with a total attrition of more than 30% or where differences between the groups exceeded 10%, or both, from metaâanalysis, but will include these studies in the review. </p> </section> <section id="CD002190-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We created a summary of findings tableÂ using the following outcomes: incidence of the common cold, vaccine safety, and mortality (all cause and vaccine related) (<a href="./full#CD002190-tbl-0001">summary of findings Table 1</a>)<i>.</i> We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to assess the certainty of the evidence as it relates to the study that contributed data (<a href="./references#CD002190-bbs2-0175" title="AtkinsD , BestD , BrissPA , EcclesM , Falck-YtterY , FlottorpS , GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ2004;328(7454):1490.">Atkins 2004</a>). We used the methods and recommendations described in Section 8.5 and Chapter 12 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD002190-bbs2-0206" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.">Higgins 2022</a>), employing GRADEpro GDT software (<a href="./references#CD002190-bbs2-0197" title="GRADEpro GDT. Version accessed 15 October 2016. Hamilton (ON): McMaster University (developed by Evidence Prime). Available at gradepro.org.">GRADEpro GDT</a>). We justified all decisions to downâ or upgrade the certainty of the evidence using footnotes, and made comments to aid the reader's understanding of the review where necessary. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD002190-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD002190-sec-0039"></div> <section id="CD002190-sec-0040"> <h3 class="title">Description of studies</h3> <p>SeeÂ <a href="./references#CD002190-sec-0087" title="">Characteristics of included studies</a>,Â <a href="./references#CD002190-sec-0088" title="">Characteristics of excluded studies</a>, andÂ <a href="./references#CD002190-sec-0089" title="">Characteristics of ongoing studies</a>Â tables. </p> <section id="CD002190-sec-0041"> <h4 class="title">Results of the search</h4> <p>In the current update we identified a total of 4974 search results (<a href="#CD002190-fig-0001">Figure 1</a>). We used Cochraneâs Screen4Me workflow to help identify potential reports of randomised trials. The results of the Screen4Me assessment process are shown inÂ <a href="#CD002190-fig-0002">Figure 2</a>. We assessed 6132 records and excluded 3657 records based on title and abstract screening. We assessed the full texts of 165 studies, and did not include any new studies in this update. We included only one trial in the review (<a href="./references#CD002190-bbs2-0001" title="GriffinJP , GreenbergBH . Live and inactivated adenovirus vaccines. Clinical evaluation of efficacy in prevention of acute respiratory disease. Archives of Internal Medicine1970;125(6):981-6. [PMID: 4378136]">Griffin 1970</a>). </p> <div class="figure" id="CD002190-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Screen4Me summary diagram." data-id="CD002190-fig-0002" src="/cdsr/doi/10.1002/14651858.CD002190.pub6/media/CDSR/CD002190/image_n/nCD002190-FIG-02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Screen4Me summary diagram.</p> </div> </div> </div> </section> <section id="CD002190-sec-0042"> <h4 class="title">Included studies</h4> <p>We included one RCT involving 2307 healthy young men (<a href="./references#CD002190-bbs2-0001" title="GriffinJP , GreenbergBH . Live and inactivated adenovirus vaccines. Clinical evaluation of efficacy in prevention of acute respiratory disease. Archives of Internal Medicine1970;125(6):981-6. [PMID: 4378136]">Griffin 1970</a>).Â <a href="./references#CD002190-bbs2-0001" title="GriffinJP , GreenbergBH . Live and inactivated adenovirus vaccines. Clinical evaluation of efficacy in prevention of acute respiratory disease. Archives of Internal Medicine1970;125(6):981-6. [PMID: 4378136]">Griffin 1970</a>Â compared the effect of three adenovirus vaccines (live, inactivated type 4, and inactivated type 4 and 7) to placebo (an injection of physiological saline for the parenterally administered vaccines, and an identicalâappearing inert gelatin capsule for the orally administered vaccines). See <a href="./references#CD002190-sec-0087" title="">Characteristics of included studies</a>. </p> </section> <section id="CD002190-sec-0043"> <h4 class="title">Excluded studies</h4> <p>We excluded 43 studies in the previous publication of this review (<a href="./references#CD002190-bbs2-0008" title="BelsheRB , Van VorisLP , MufsonMA . Parenteral administration of live respiratory syncytial virus vaccine: results of a field trial. Journal of Infectious Diseases1982;145(3):311-9. [PMID: 7037983]">Belshe 1982</a>; <a href="./references#CD002190-bbs2-0009" title="BelsheRB , KarronRA , NewmanFK , AndersonEL , NugentSL , SteinhoffM , et al. Evaluation of a live attenuated, cold-adapted parainfluenza virus type 3 vaccine in children. Journal of Clinical Microbiology1992;30(8):2064-70. [PMID: 1323576]">Belshe 1992</a>; <a href="./references#CD002190-bbs2-0010" title="BelsheRB , NewmanFK , AndersonEL , WrightPF , KarronRA , TollefsonS , et al. Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children. Journal of Infectious Diseases2004;190(12):2096-103. [PMID: 15551207]">Belshe 2004a</a>; <a href="./references#CD002190-bbs2-0011" title="BelsheRB , NewmanFK , TsaiTF , KarronRA , ReisingerK , RobertonD , et al. Phase 2 evaluation of parainfluenza type 3 cold passage mutant 45 live attenuated vaccine in healthy children 6-18 months old. Journal of Infectious Diseases2004;189(3):462-70. [PMID: 14745704]">Belshe 2004b</a>; <a href="./references#CD002190-bbs2-0015" title="ClementsML , BelsheRB , KingJ , NewmanF , WestblomTU , TierneyEL , et al. Evaluation of bovine, cold-adapted human, and wild-type human parainfluenza type 3 viruses in adult volunteers and in chimpanzees. Journal of Clinical Microbiology1991;29(6):1175-82. [PMID: 1650789]">Clements 1991</a>; <a href="./references#CD002190-bbs2-0017" title="DeVincenzoJ , Lambkin-WilliamsR , WilkinsonT , CehelskyJ , NochurS , WalshE , et al. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proceedings of the National Academy of Sciences of the United States of America2010;107(19):8800-5. [PMID: 20421463]">DeVincenzo 2010</a>; <a href="./references#CD002190-bbs2-0019" title="DoggettJE , BynoeML , TyrrellDA . Some attempts to produce an experimental vaccine with rhinoviruses. British Medical Journal1963;1(5322):34-6. [PMID: 14028369]">Doggett 1963</a>; <a href="./references#CD002190-bbs2-0022" title="DuddingBA , BartelloniPJ , ScottRM , Top FH Jr, RussellPK , BuescherEL . Enteric immunization with live adenovirus type 21 vaccine I. Tests for safety, infectivity, immunogenicity, and potency in volunteers. Infection and Immunity1972;5(3):295-9. [PMID: 4564559]">Dudding 1972</a>; <a href="./references#CD002190-bbs2-0036" title="FalseyAR , WalshEE . Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60. Vaccine1996;14(13):1214-8. [PMID: 8961507]">Falsey 1996</a>; <a href="./references#CD002190-bbs2-0037" title="FalseyAR , WalshEE , CapellanJ , GravensteinS , ZambonM , YauE , et al. Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (RSV) vaccines - nonadjuvanted vaccine or vaccine adjuvanted with alum-given concomitantly with influenza vaccine to high-risk elderly individuals. Journal of Infectious Diseases2008;198(9):1317-26. [PMID: 18855558]">Falsey 2008</a>; <a href="./references#CD002190-bbs2-0039" title="FulginitiVA , EllerJJ , SieberOF , JoynerJW , MinamitaniM , MeiklejohnG . Respiratory virus immunization I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. American Journal of Epidemiology1969;89(4):435-48. [PMID: 4305199]">Fulginiti 1969</a>; <a href="./references#CD002190-bbs2-0040" title="GlennGM , FriesLF , ThomasDN , SmithG , KpameganE , LuH , et al. A randomized, blinded, controlled, dose-ranging study of a respiratory syncytial virus recombinant fusion (F) nanoparticle vaccine in healthy women of childbearing age. Journal of Infectious Diseases2016;213(3):411-22. [DOI: 10.1093/infdis/jiv406] [PMID: 26259809]">Glenn 2016</a>; <a href="./references#CD002190-bbs2-0041" title="GomezM , MufsonMA , DubovskyF , KnightlyC , ZengW , LosonskyG . Phase-I study MEDI-534, of a live, attenuated intranasal vaccine against respiratory syncytial virus and parainfluenza-3 virus in seropositive children. Pediatric Infectious Disease Journal2009;28(7):655-8. [PMID: 19483659]">Gomez 2009</a>; <a href="./references#CD002190-bbs2-0042" title="GonzalezIM , KarronRA , EichelbergerM , WalshEE , DelagarzaVW , BennettR , et al. Evaluation of the live attenuated cpts 248/404 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young and older adults. Vaccine2000;18(17):1763-72. [PMID: 10699324]">Gonzalez 2000</a>; <a href="./references#CD002190-bbs2-0043" title="GreenbergDP , WalkerRE , LeeMS , ReisingerKS , WardJI , YogevR , et al. A bovine parainfluenza virus type 3 vaccine is safe and immunogenic in early infancy. Journal of Infectious Diseases2005;191(7):1116-22. [PMID: 15747247]">Greenberg 2005</a>; <a href="./references#CD002190-bbs2-0044" title="HamoryBH , HamparianVV , ConantRM , GwaltneyJM . Human responses to two decavalent rhinovirus vaccines. Journal of Infectious Diseases1975;132(6):623-9. [PMID: 172561]">Hamory 1975</a>; <a href="./references#CD002190-bbs2-0047" title="KarronRA , WrightPF , HallSL , MakheneM , ThompsonJ , BurnsBA , et al. A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children. Journal of Infectious Diseases1995;171(5):1107-14. [PMID: 7751684]">Karron 1995a</a>; <a href="./references#CD002190-bbs2-0048" title="KarronRA , WrightPF , NewmanFK , MakheneM , ThompsonJ , SamorodinR , et al. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in healthy infants and children. Journal of Infectious Diseases1995;172(6):1445-50. [PMID: 7594701]">Karron 1995b</a>; <a href="./references#CD002190-bbs2-0049" title="KarronRA , WrightPF , CroweJE , Clements-MannML , ThompsonJ , MakheneM , et al. Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children. Journal of Infectious Diseases1997;176(6):1428-36. [PMID: 9395351]">Karron 1997</a>; <a href="./references#CD002190-bbs2-0050" title="KarronRA , BelsheRB , WrightPF , ThumarB , BurnsB , NewmanF , et al. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants. Pediatric Infectious Disease Journal2003;22(5):394-405. [PMID: 12792378]">Karron 2003</a>; <a href="./references#CD002190-bbs2-0051" title="KarronRA , WrightPF , BelsheRB , ThumarB , CaseyR , NewmanF , et al. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. Journal of Infectious Diseases2005;191(7):1093-104. [PMID: 15747245]">Karron 2005</a>; <a href="./references#CD002190-bbs2-0052" title="KarronRA , San MateoJ , ThumarB , Schaap-NuttA , BuchholzUJ , SchmidtAC , et al. Evaluation of a live-attenuated human parainfluenza type 1 vaccine in adults and children. Journal of Pediatric Infectious Diseases Society2015;4(4):e143-6. [DOI: 10.1093/jpids/piu104] [PMID: 26582883]">Karron 2015</a>; <a href="./references#CD002190-bbs2-0055" title="KumpuM , KekkonenRA , KorpelaR , TynkkynenS , JÃ¤rvenpÃ¤Ã¤S , KautiainenH , et al. Effect of live and inactivated Lactobacillus rhamnosus GG on experimentally induced rhinovirus colds: randomised, double blind, placebo-controlled pilot trial. Beneficial Microbes2015;6(5):631-9. [DOI: 10.3920/BM2014.0164] [PMID: 26322544]">Kumpu 2015</a>; <a href="./references#CD002190-bbs2-0056" title="LangleyJM , SalesV , McGeerA , GuaspariniR , PredyG , MeekisonW , et al. A dose-ranging study of a subunit respiratory syncytial virus subtype A vaccine with and without aluminum phosphate adjuvantation in adults &gt; or = 65 years of age. Vaccine2009;27(42):5913-9. [PMID: 19651171]">Langley 2009</a>; <a href="./references#CD002190-bbs2-0060" title="LeeMS , GreenbergDP , YehSH , YogevR , ReisingerKS , WardJI , et al. Antibody responses to bovine parainfluenza virus type 3 (PIV3) vaccination and human PIV3 infection in young infants. Journal of Infectious Diseases2001;184(7):909-13. [PMID: 11509996]">Lee 2001</a>; <a href="./references#CD002190-bbs2-0061" title="LeeFE , WalshEE , FalseyAR , BettsRF , TreanorJJ . Experimental infection of humans with A2 respiratory syncytial virus. Antiviral Research2004;63(3):191-6. [PMID: 15451187]">Lee 2004</a>; <a href="./references#CD002190-bbs2-0063" title="LyonsA , LongfieldJ , KuschnerR , StraightT , BinnL , SeriwatanaJ , et al. A double-blind, placebo-controlled study of the safety and immunogenicity of live, oral type 4 and type 7 adenovirus vaccines in adults. Vaccine2008;26(23):2890-8. [PMID: 18448211]">Lyons 2008</a>; <a href="./references#CD002190-bbs2-0064" title="MadhiSA , CutlandC , ZhuY , HackellJG , NewmanF , BlackburnN , et al. Transmissibility, infectivity and immunogenicity of a live human parainfluenza type 3 virus vaccine (HPIV3cp45) among susceptible infants and toddlers. Vaccine2006;24(13):2432-9. [PMID: 16406170]">Madhi 2006</a>; <a href="./references#CD002190-bbs2-0069" title="MunozFM , PiedraPA , GlezenWP . Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women. Vaccine2003;21(24):3465-7. [PMID: 12850361]">Munoz 2003</a>; <a href="./references#CD002190-bbs2-0071" title="MurphyBR , HallSL , KulkarniAB , CroweJE , CollinsPL , ConnorsM , et al. An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines. Virus Research1994;32(1):13-36. [PMID: 8030364]">Murphy 1994</a>; <a href="./references#CD002190-bbs2-0126" title="ParadisoPR , HildrethSW , HogermanDA , SpeelmanDJ , LewinEB , OrenJ , et al. Safety and immunogenicity of a subunit respiratory syncytial virus vaccine in children 24 to 48 months old. Pediatric Infectious Disease Journal1994;13(9):792-8. [PMID: 7808848]">Paradiso 1994</a>; <a href="./references#CD002190-bbs2-0129" title="PiedraPA , GlezenWP , KaselJA , WelliverRC , JewelAM , RayfordY , et al. Safety and immunogenicity of the PFP vaccine against respiratory syncytial virus (RSV): the western blot assay aids in distinguishing immune responses of the PFP vaccine from RSV infection. Vaccine1995;13(12):1095-101. [PMID: 7491817]">Piedra 1995</a>; <a href="./references#CD002190-bbs2-0130" title="PierceWE , RosenbaumMJ , EdwardsEA , PeckinpaughRO , JacksonGG . Live and inactivated adenovirus vaccines for the prevention of acute respiratory illness in naval recruits. American Journal of Epidemiology1968;87(1):237-46. [PMID: 4295428]">Pierce 1968</a>; <a href="./references#CD002190-bbs2-0131" title="PowerUF , NguyenTN , RietveldE , deSwartRL , GroenJ , OsterhausAD , et al. Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine (BBG2Na) in healthy young adults. Journal of Infectious Diseases2001;184(11):1456-60. [PMID: 11709789]">Power 2001</a>; <a href="./references#CD002190-bbs2-0132" title="RitchieJM . Autogenous vaccine in prophylaxis of the common cold. Lancet1958;1(7021):615-8. [PMID: 13515297]">Ritchie 1958</a>; <a href="./references#CD002190-bbs2-0141" title="SimoesEA , TanDH , OhlssonA , SalesV , WangEE . Respiratory syncytial virus vaccine: a systematic overview with emphasis on respiratory syncytial virus subunit vaccines. Vaccine2001;20(5-6):954-60. [PMID: 11738763]">Simoes 2001</a>; <a href="./references#CD002190-bbs2-0143" title="TangRS , SpaeteRR , ThompsonMW , MacPhailM , GuzzettaJM , RyanPC , et al. Development of a PIV-vectored RSV vaccine: preclinical evaluation of safety, toxicity, and enhanced disease and initial clinical testing in healthy adults. Vaccine2008;26(50):6373-82. [PMID: 18822334]">Tang 2008</a>; <a href="./references#CD002190-bbs2-0144" title="Top FH Jr, BuescherEL , BancroftWH , RussellPK . Immunization with live types 7 and 4 adenovirus vaccines. II. Antibody response and protective effect against acute respiratory disease due to adenovirus type 7. Journal of Infectious Diseases1971;124(2):155-60. [PMID: 4330998]">Top 1971</a>; <a href="./references#CD002190-bbs2-0145" title="TristramDA , WelliverRC , MoharCK , HogermanDA , HildrethSW , ParadisoP . Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18-36 months old. Journal of Infectious Diseases1993;167(1):191-5. [PMID: 8418166]">Tristram 1993</a>; <a href="./references#CD002190-bbs2-0148" title="WattPJ , RobinsonBS , PringleCR , TyrrellDA . Determinants of susceptibility to challenge and the antibody response of adult volunteers given experimental respiratory syncytial virus vaccines. Vaccine1990;8(3):231-6. [PMID: 2363300]">Watt 1990</a>; <a href="./references#CD002190-bbs2-0149" title="WelliverRC , TristramDA , BattK , SunM , HogermanD , HildrethS . Respiratory syncytial virus-specific cell-mediated immune responses after vaccination with a purified fusion protein subunit vaccine. Journal of Infectious Diseases1994;170(2):425-8. [PMID: 8035030]">Welliver 1994</a>; <a href="./references#CD002190-bbs2-0151" title="WilsonJS , GrantPJ , MillerDL , TaylorCE , McDonaldJC . Trial of adenovirus vaccine in Royal Air Force recruits. British Medical Journal1960;1(5179):1081-3. [PMID: 13845090]">Wilson 1960</a>; <a href="./references#CD002190-bbs2-0152" title="WrightPF , ShinozakiT , FleetW , SellSH , ThompsonJ , KarzonDT . Evaluation of a live, attenuated respiratory syncytial virus vaccine in infants. Journal of Pediatrics1976;88(6):931-6. [PMID: 178852]">Wright 1976</a>).Â  </p> <p>We excluded 109 new studies in this update (<a href="./references#CD002190-bbs2-0002" title="AbarcaK , Rey-JuradoE , MuÃ±oz-DurangoN , VÃ¡zquezY , SotoJA , GÃ¡lvezN , et al. Safety and immunogenicity evaluation of recombinant BCG vaccine against respiratory syncytial virus in a randomized, double-blind, placebo-controlled phase I clinical trial. EClinicalMedicine2020;27:100517. [DOI: 10.1016/j.eclinm.2020.100517] [PMID: 33073219]">Abarca 2020</a>; <a href="./references#CD002190-bbs2-0003" title="AhmadA , EzeK , NoulinN , HorvathovaV , MurrayB , BailletM , et al. EDP-938, a respiratory syncytial virus inhibitor, in a human virus challenge. New England Journal of Medicine2022;386(7):655-66. [DOI: 10.1056/NEJMoa2108903] [PMID: 35172056]">Ahmad 2022</a>; <a href="./references#CD002190-bbs2-0004" title="AliprantisA , WolfordD , CaroL , MaasB , MaH , VoraK , et al. A randomized, double-blind, placebo-controlled trial to assess the safety and tolerability of a respiratory syncytial virus (RSV) neutralizing monoclonal antibody (MK-1654) in healthy subjects. Open Forum Infectious Diseases2018;5(Suppl 1):572. [DOI: 10.1093/ofid/ofy210.1627]">Aliprantis 2018</a>; <a href="./references#CD002190-bbs2-0005" title="AliprantisAO , ShawCA , GriffinP , FarinolaN , RailkarRA , CaoX , et al. A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults. Human Vaccines and Immunotherapeutics2020;17(5):1248-61. [DOI: 10.1080/21645515.2020.1829899] [PMID: 33121346]">Aliprantis 2020</a>; <a href="./references#CD002190-bbs2-0006" title="AscoughS , VlachantoniI , KalyanM , HaijemaBJ , Wallin-WeberS , Dijkstra-TiekstraM , et al. Local and systemic immunity against respiratory syncytial virus induced by a novel intranasal vaccine a randomized, double-blind, placebo-controlled clinical trial. American Journal of Respiratory and Critical Care Medicine2019;200(4):481-92. [DOI: 10.1164/rccm.201810-1921OC]">Ascough 2019</a>; <a href="./references#CD002190-bbs2-0007" title="AugustA , GlennGM , KpameganE , HickmanSP , JaniD , LuH , et al. A phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age. Vaccine2017;35(30):3749-59. [DOI: 10.1016/j.vaccine.2017.05.045]">August 2017</a>; <a href="./references#CD002190-bbs2-0012" title="BeranJ , LickliterJD , SchwarzTF , JohnsonC , ChuL , DomachowskeJB , et al. Safety and immunogenicity of 3 formulations of an investigational respiratory syncytial virus vaccine in nonpregnant women: results from 2 phase 2 trials. Journal of Infectious Diseases2018;217(10):1616-25. [DOI: 10.1093/infdis/jiy065]">Beran 2018</a>; <a href="./references#CD002190-bbs2-0013" title="BourneLB . Trial of an oral vaccine against bacterial infection accompanying the common cold. Nature1946;157:591. [DOI: 10.1038/157591b0]">Bourne 1946</a>; <a href="./references#CD002190-bbs2-0014" title="CicconiP , JonesC , SarkarE , Silva-ReyesL , KlenermanP , De LaraC , et al. First-in-human randomized study to assess the safety and immunogenicity of an investigational respiratory syncytial virus (RSV) vaccine based on chimpanzee-adenovirus-155 viral vectorâexpressing RSV fusion, nucleocapsid, and antitermination viral proteins in healthy adults. Clinical Infectious Diseases2020;70(10):2073â81. [DOI: 10.1093/cid/ciz653]">Cicconi 2020</a>; <a href="./references#CD002190-bbs2-0016" title="CunninghamCK , KarronR , MuresanP , McFarlandEJ , PerlowskiC , LibousJ , et al. Live-attenuated respiratory syncytial virus vaccine with deletion of RNA synthesis regulatory protein M2-2 and cold passage mutations is overattenuated. Open Forum Infectious Diseases2019;6(6):ofz212. [DOI: 10.1093/ofid/ofz212] [PMID: 31211158]">Cunningham 2019</a>; <a href="./references#CD002190-bbs2-0018" title="DeVincenzoJ , GymnopoulouE , De PaepeE , MurrayB , BastianAR , HaazenW . A randomized, double-blind, placebo-controlled study to evaluate the efficacy of a single immunization of AD26.RSV.Pref against RSV infection in a viral challenge model in healthy adults. Open Forum Infectious Diseases2019;6(Suppl):27-8. [DOI: 10.1093/ofid/ofz359.061]">DeVincenzo 2019</a>; <a href="./references#CD002190-bbs2-0020" title="DomachowskeJB , KhanA , EsserMT , JensenKM , TakasT , VillafanaT , et al. AÂ single dose monoclonal antibody (mAb) immunoprophylaxis strategy to prevent RSV disease in all infants: results of the first in infant study with MEDI8897. Open Forum Infectious Diseases2017;4(Suppl 1):S37. [DOI: 10.1093/ofid/ofx162.089] [PMID: PMC5631822]">Domachowske 2017</a>; <a href="./references#CD002190-bbs2-0021" title="DomachowskeJB , KhanAA , JensenK , TakasT , VillafanaT , DubovskyF , et al. A single dose monoclonal antibody immunoprophylaxis strategy to prevent respiratory syncytial virus disease in all infants: results of the first in infant study with MEDI8897. Pediatrics2018;141(1):256. [DOI: 10.1542/peds.141.1_MeetingAbstract.256]">Domachowske 2018</a>; <a href="./references#CD002190-bbs2-0023" title="EspositoS , BianchiniS , BosisS , TagliabueC , CoroI , ArgentieroA , et al. A randomized, placebo-controlled, double-blinded, single-centre, phase IV trial to assess the efficacy and safety of OM-85 in children suffering from recurrent respiratory tract infections. Journal of Translational Medicine2019;17(1):284. [DOI: 10.1186/s12967-019-2040-y]">Esposito 2019</a>; <a href="./references#CD002190-bbs2-0024" title="EUCTR2008-001714-24-GB. A phase II, double-blind placebo-controlled study to determine the prophylactic efficacy of oral BTA798 in an experimental rhinovirus challenge model. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2008%E2%80%90001714%E2%80%9024%E2%80%90GB (first received 18 June 2008). ">EUCTR2008â001714â24âGB</a>; <a href="./references#CD002190-bbs2-0025" title="EUCTR2012-001107-20-GB. A phase 2a randomised, double-blind, placebo-controlled repeat dose trial of the activity of MDT-637 in healthy subjects challenged with RSV-A (Memphis 37b) - phase 2a trial of MDT-637 in healthy subjects challenged with RSV. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2012%E2%80%90001107%E2%80%9020%E2%80%90GB (first received 2 August 2013). ">EUCTR2012â001107â20âGB</a>; <a href="./references#CD002190-bbs2-0026" title="EUCTR2013-004036-30-GB. A randomised, phase 2a, double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics and antiviral activity of multiple doses of orally administered ALS-008176 against respiratory syncytial virus infection in the virus challenge model - phase 2a, double blind, placebo-controlled, viral challenge study. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013%E2%80%90004036%E2%80%9030%E2%80%90GB (first received 29 November 2013). ">EUCTR2013â004036â30âGB</a>; <a href="./references#CD002190-bbs2-0027" title="EUCTR2014-005041-41-GB. A phase 2a, randomized, double-blinded, placebo-controlled study to evaluate the antiviral activity, safety, and pharmacokinetics of repeated doses of orally administered JNJ-53718678 against respiratory syncytial virus infection in the virus challenge model in healthy adult subjects. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2014%E2%80%90005041%E2%80%9041%E2%80%90GB (first received 24 April 2015). ">EUCTR2014â005041â41âGB</a>; <a href="./references#CD002190-bbs2-0028" title="EUCTR2015-004296-77-GB. A randomised, phase 2a, doubleâblind, placeboâcontrolled study to evaluate the safety and antiviral activity against respiratory syncytial virus infection, and the pharmacokinetics of multiple oral doses of BTAâC585 in the virus challenge model. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2015%E2%80%90004296%E2%80%9077%E2%80%90GB (first received 8 February 2016). ">EUCTR2015â004296â77âGB</a>; <a href="./references#CD002190-bbs2-0029" title="EUCTR2016-000117-76-ES. A study to evaluate safety, reactogenicity and immunogenicity of GSK biologicalsâ RSV investigational vaccine based on viral proteins encoded by chimpanzee-derived adenovector (ChAd155-RSV) (GSK3389245A) in RSV-seropositive infants. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2016%E2%80%90000117%E2%80%9076%E2%80%90ES (first received 5 August 2016). ">EUCTR2016â000117â76âES</a>; <a href="./references#CD002190-bbs2-0030" title="EUCTR2016-000117-76-PL. A study to evaluate safety and immunogenicity of GSK biologicalsâ RSV investigational vaccine in RSV-seropositive infants aged 12 to 23 months. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2016%E2%80%90000117%E2%80%9076%E2%80%90PL (first received 6 June 2018). ">EUCTR2016â000117â76âPL</a>; <a href="./references#CD002190-bbs2-0031" title="EUCTR2016-001135-12-FR. A study to rank different dosages of antigen of GlaxoSmithKline (GSK) biologicalsâ investigational respiratory syncytial virus (RSV) vaccine (GSK3003891A), based on their immune response and safety, when administered to healthy adult women. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2016%E2%80%90001135%E2%80%9012%E2%80%90FR (first received 14 December 2016). ">EUCTR2016â001135â12âFR</a>; <a href="./references#CD002190-bbs2-0032" title="EUCTR2016-002733-30-ES. A study to evaluate the safety, reactogenicity and immunogenicity of the GSK investigational vaccine GSK3003891A in healthy pregnant women and infants born to vaccinated mothers. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2016%E2%80%90002733%E2%80%9030%E2%80%90ES (first received 8 February 2017). ">EUCTR2016â002733â30âES</a>; <a href="./references#CD002190-bbs2-0033" title="EUCTR2018-001340-62-FI. A study to evaluate different dose levels of GlaxoSmithKline (GSK) biologicals' investigational respiratory syncytial virus (RSV) vaccine (GSK3888550A), based on the safety of the vaccine and the antibodies (body defences) that the body produces following the vaccine administration, when given to healthy non-pregnant women. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2018%E2%80%90001340%E2%80%9062%E2%80%90FI (first received 17 October 2018). ">EUCTR2018â001340â62âFI</a>; <a href="./references#CD002190-bbs2-0034" title="FalloonJ , TalbotHK , CurtisC , ErvinJ , KriegerD , DubovskyF , et al. Dose selection for an adjuvanted respiratory syncytial virus F protein vaccine for older adults based on humoral and cellular immune responses. Clinical and Vaccine Immunology2017;24(9):e00157-17. [DOI: 10.1128/CVI.00157-17]">Falloon 2017a</a>; <a href="./references#CD002190-bbs2-0035" title="FalloonJ , YuJ , EsserMT , VillafanaT , YuL , DubovskyF , et al. An adjuvanted, postfusion F protein-based vaccine did not prevent respiratory syncytial virus illness in older adults. Journal of Infectious Diseases2017;216(11):1362-70. [DOI: 10.1093/infdis/jix503]">Falloon 2017b</a>; <a href="./references#CD002190-bbs2-0038" title="FriesLF , ChoI , ThomasDN , WenJL , SpindlerMS , FixAB , et al. Third trimester immunization with an respiratory syncytial virus F protein vaccine for the prevention of RSV lower respiratory tract infection in infants. Open Forum Infectious Diseases2019;6(Suppl):921-2. [DOI: 10.1093/ofid/ofz360.2315]">Fries 2019</a>; <a href="./references#CD002190-bbs2-0045" title="IsraelS , RuschS , DeVincenzoJ , BoyersA , Fok-SeangJ , HuntjensD , et al. Effect of oral JNJ-53718678 (JNJ-678) on disease severity in healthy adult volunteers experimentally inoculated with live respiratory syncytial virus (RSV): a placebo-controlled challenge study. Open Forum Infectious Diseases2016;3(Suppl 1):650. [DOI: 10.1093/ofid/ofw172.513]">Israel 2016</a>; <a href="./references#CD002190-bbs2-0046" title="KarppinenS , ToivonenL , Schuez-HavupaloL , Teros-JaakkolaT , WarisM , AuranenK , et al. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against all respiratory tract infections in children under two years of age. Vaccine2019;37(22):2935-41. [DOI: 10.1016/j.vaccine.2019.04.026]">Karppinen 2019</a>; <a href="./references#CD002190-bbs2-0053" title="KarronRA , AtwellJE , McFarlandEJ , CunninghamCK , MuresanP , PerlowskiC . Live-attenuated vaccines prevent respiratory syncytial virus-associated illness in young children. American Journal of Respiratory and Critical Care Medicine2021;203(5):594-603. [DOI: 10.1164/rccm.202005-1660OC] [PMID: 32871092]">Karron 2020a</a>; <a href="./references#CD002190-bbs2-0054" title="KarronRA , LuongoC , MateoJS , WanionekK , CollinsPL , BuchholzUJ . Safety and immunogenicity of the respiratory syncytial virus vaccine RSV/DELTANS2/DELTA1313/I1314L in RSV-seronegative children. Journal of Infectious Diseases2020;222(1):82-91. [DOI: 10.1093/infdis/jiz408] [PMID: 31605113]">Karron 2020b</a>; <a href="./references#CD002190-bbs2-0057" title="LangleyJ , MacdonaldL , WeirG , Mackinnon-CameronD , YeL , McNeilS , et al. A phase I randomized, observer-blind, controlled, dose escalation trial of the safety and tolerability of two intramuscular doses of DPXRSV (A), a respiratory syncytial virus (RSV) vaccine containing RSV SH antigen and a novel adjuvant depovax, or SH antigen and a novel adjuvant DepoVax, or SH antigen co-administered with aluminum hydroxide, or placebo to healthy adults â¥ 50â64 years of age. Open Forum Infectious Diseases2016;3:ofw172.97. [DOI: 10.1093/ofid/ofw172.973]">Langley 2016</a>; <a href="./references#CD002190-bbs2-0058" title="LangleyJM , AggarwalN , TomaA , HalperinSA , McNeilSA , FissetteL , et al. A randomized, controlled, observer-blinded phase 1 study of the safety and immunogenicity of a respiratory syncytial virus vaccine with or without alum adjuvant. Journal of Infectious Diseases2017;215(1):24-33. [DOI: 10.1093/infdis/jiw453]">Langley 2017</a>; <a href="./references#CD002190-bbs2-0059" title="LangleyJ , MacdonaldL , WeirG , Mackinnon-CameronD , YeL , McneilS , et al. A respiratory syncytial virus vaccine based on the small hydrophobic protein ectodomain presented with a novel lipid-based formulation is highly immunogenic and safe in adults: a first-in-humans study. Journal of Infectious Diseases2018;218(3):378-87. [DOI: 10.1093/infdis/jiy177]">Langley 2018</a>; <a href="./references#CD002190-bbs2-0062" title="Leroux-RoelsG , De BoeverF , MaesC , Nguyen TL-A, BakerS , Gonzalez LopezA . Safety and immunogenicity of a respiratory syncytial virus fusion glycoprotein F subunit vaccine in healthy adults: results of a phase 1, randomized, observer-blind, controlled, dosage-escalation study. Vaccine2019;37(20):2694-703. [DOI: 10.1016/j.vaccine.2019.04.011]">LerouxâRoels 2019</a>; <a href="./references#CD002190-bbs2-0065" title="MadhiSA , PolackFP , PiedraPA , MunozFM , TrenholmeAA , SimÃµesE , et al. Respiratory syncytial virus vaccination during pregnancy and effects in infants. New England Journal of Medicine2020;383(5):426-39. [DOI: 10.1056/NEJMoa1908380] [PMID: 32726529]">Madhi 2020</a>; <a href="./references#CD002190-bbs2-0066" title="McFarlandEJ , KarronRA , MuresanP , CunninghamCK , ValentineME , PerlowskiC , et al. Live-attenuated respiratory syncytial virus vaccine candidate with deletion of RNA synthesis regulatory protein M2-2 is highly immunogenic in children. Journal of Infectious Diseases2018;217(9):1347-55. [DOI: 10.1093/infdis/jiy040] [PMID: 29509911]">McFarland 2018</a>; <a href="./references#CD002190-bbs2-0067" title="McFarlandEJ , KarronRA , MuresanP , CunninghamCK , PerlowskiC , LibousJ , et al. Live respiratory syncytial virus attenuated by M2-2 deletion and stabilized temperature sensitivity mutation 1030s is a promising vaccine candidate in children. Journal of Infectious Diseases2020;221(4):534-43. [DOI: 10.1093/infdis/jiz603]">McFarland 2020a</a>; <a href="./references#CD002190-bbs2-0068" title="McFarlandEJ , KarronRA , MuresanP , CunninghamCK , PerlowskiC , LibousJ , et al. Live-attenuated respiratory syncytial virus vaccine with M2-2 deletion and with small hydrophobic noncoding region is highly immunogenic in children. Journal of Infectious Diseases2020;221(12):2050-9. [DOI: 10.1093/infdis/jiaa049]">McFarland 2020b</a>; <a href="./references#CD002190-bbs2-0070" title="MuÅozFM , SwamyGK , HickmanSP , AgrawalS , PiedraPA , GlennGM , et al. Safety and immunogenicity of a respiratory syncytial virus fusion (F) protein nanoparticle vaccine in healthy third-trimester pregnant women and their infants. Journal of Infectious Diseases2019;220(11):1802-15. [DOI: 10.1093/infdis/jiz390]">Munoz 2019</a>; <a href="./references#CD002190-bbs2-0072" title="NCT00139347. A multi-country &amp; multi-center study to assess the efficacy, immunogenicity &amp; safety of two doses of GSK biologicals' oral live attenuated HRV vaccine given concomitantly with routine EPI vaccinations including OPV in healthy infants. clinicaltrials.gov/show/NCT00139347 (first received 31 August 2005). ">NCT00139347</a>; <a href="./references#CD002190-bbs2-0073" title="NCT00308412. Safety of and immune response to a human parainfluenza virus vaccine (rHPIV3cp45) in healthy infants [Phase 1 study to determine the safety, infectivity, and tolerability of two doses of live attenuated recombinant cold passaged (cp) 45 parainfluenza type 3 virus vaccine, rHPIV3cp45,Â lot PIV3 102A, delivered as nose drops to infants 6 to 12 months of age, and to HPIV3 seronegative infants and children 6 to 36 months of age]. clinicaltrials.gov/show/NCT00308412 (first received 29 March 2006). ">NCT00308412</a>; <a href="./references#CD002190-bbs2-0074" title="NCT00345670. Study to evaluate the safety of MEDI-534 vaccine against respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) in healthy children [A phaseÂ I, randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the safety, tolerability, immunogenicity, and viral shedding of MEDI-534, a live, attenuated intranasal vaccine against respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3), inÂ healthy RSV and PIV3 seropositive 1-9 year-old children]. clinicaltrials.gov/show/NCT00345670 (first received 28 June 2006). ">NCT00345670</a>; <a href="./references#CD002190-bbs2-0075" title="NCT00345956. To evaluate immunogenicity, reactogenicity &amp; safety of 2 doses of GSK Bio HRV liquid vaccine given to infants (Vietnam) [A placebo-controlled study to evaluate the immunogenicity, reactogenicity and safety of two doses of GSK biologicals' oral live attenuated human rotavirus (HRV) liquid vaccine, when given to healthy infants, in Vietnam]. clinicaltrials.gov/show/NCT00345956 (first received 29 June 2006). ">NCT00345956</a>; <a href="./references#CD002190-bbs2-0076" title="NCT00363545. To assess immunogenicity, reactogenicity &amp; safety of 2 formulations of GSK's HRV vaccine as 2-dose vaccination (Infants) [A study to assess the immunogenicity, reactogenicity and safety of 2 different formulations of GSK biologicals' live attenuated HRV vaccine, given as a two-dose primary vaccination, in healthy infants previously uninfected with HRV]. clinicaltrials.gov/ct2/show/NCT00363545 (first received 15 August 2006). ">NCT00363545</a>; <a href="./references#CD002190-bbs2-0077" title="NCT00366782. Safety of and immune response to a cow/human parainfluenza virus vaccine (rB/HPIV3) in healthy infants, children, and adults [A phase 1 study of the safety and immunogenicity of the recombinant live-attenuated chimeric bovine/human parainfluenza type 3 virus vaccine, rB/HPIV3,Â lot PIV3 #101A, delivered as nose drops to adults 18 to 49 years of age, HPIV3-seropositive children 15 to 59 months of age, and HPIV3-seronegative infants and children 6 to 36 months of age]. clinicaltrials.gov/ct2/show/NCT00366782 (first received 21 August 2006). ">NCT00366782</a>; <a href="./references#CD002190-bbs2-0078" title="NCT00383903. Evaluate safety &amp; immunogenicity of 2 or 3 doses of GSK HRV vaccine in healthy infants in South Africa [AÂ phase II, randomized, double-blind, placebo-controlled study of safety, reactogenicity and immunogenicity of 2 or 3 doses of GSK biologicals' oral live attenuated human rotavirus vaccine at 10E6.5 CCID50 viral concentration in healthy infants (approximately 5-10 weeks old) in the Republic of South Africa]. clinicaltrials.gov/ct2/show/NCT00383903 (first received 4 October 2006). ">NCT00383903</a>; <a href="./references#CD002190-bbs2-0079" title="NCT00420316. Long-term efficacy and safety of subjects approximately 3 years after priming with 2 doses of GSK Bio's HRV vaccine [To assess long-term efficacy &amp; safety of subjects approximately 3 years after priming with 2 doses of GlaxoSmithKline (GSK) biologicals' oral live attenuated human rotavirus (HRV)Â vaccine (Rotarix) in the primary vaccination study (102247)]. clinicaltrials.gov/ct2/show/NCT00420316 (first received 11 January 2007). ">NCT00420316</a>; <a href="./references#CD002190-bbs2-0080" title="NCT00496821. Intranasal ALN-RSV01 administered to adult volunteers experimentally inoculated with respiratory syncytial virus [A study to investigate the safety and efficacy of intranasal ALN-RSV01 administered to adult volunteers experimentally inoculated with respiratory syncytial virus]. clinicaltrials.gov/ct2/show/NCT00496821 (first received 4 July 2007). ">NCT00496821</a>; <a href="./references#CD002190-bbs2-0081" title="NCT00641017. Safety of and immune response to recombinant live-attenuated parainfluenza type 1 virus vaccine [AÂ phase I study of the safety and immunogenicity of the recombinant live-attenuated human parainfluenza type 1 virus vaccine, rHPIV1 84/del170/942A,Â lot PIV1 #104A, delivered as nose drops to adults 18 to 49 years of age, HPIV1-seropositive children 15 to 59 months of age, and hpiv1-seronegative infants and children 6 to 59 months of age]. clinicaltrials.gov/ct2/show/NCT00641017 (first received 21 March 2008). ">NCT00641017</a>; <a href="./references#CD002190-bbs2-0082" title="NCT00686075. A study to evaluate the safety, tolerability, immunogenicity and vaccine-like viral shedding of MEDI-534, against respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3), in healthy 6 to &lt; 24 month-old children and in 2 month-old infants [AÂ phase 1/2a, randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the safety, tolerability, immunogenicity and vaccine-like viral shedding of MEDI-534, a live, attenuated intranasal vaccine against respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3), in healthy 6 to &lt; 24 month-old children and in 2 month-old infants]. clinicaltrials.gov/ct2/show/NCT00686075 (first received 29 May 2008). ">NCT00686075</a>; <a href="./references#CD002190-bbs2-0083" title="NCT00767416. A randomized, double-blind, placebo-controlled study to evaluate safety of MEDI-559 in healthy 1 to &lt; 24 month-old children [AÂ phase 1/2a, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, immunogenicity, and viral shedding of MEDI-559, a live attenuated intranasal vaccine against respiratory syncytial virus in healthy 1 to &lt;Â 24 month-old children]. clinicaltrials.gov/ct2/show/NCT00767416 (first received 7 October 2008). ">NCT00767416</a>; <a href="./references#CD002190-bbs2-0084" title="NCT01021397. Safety of and immune response to recombinant live attenuated parainfluenza type 3 virus vaccine in healthy infants and children [Phase IÂ study to determine the safety, infectivity, and tolerability of 2 doses of live attenuated recombinant cold-passaged (cp) 45 human parainfluenza type 3 virus vaccine, rHPIV3cp45,Â lot PIV3#102A, delivered as nose drops to HPIV3-seronegative infants and children 6 to 36 months of age, at a 6 month interval]. clinicaltrials.gov/ct2/show/NCT01021397 (first received 30 November 2009). ">NCT01021397</a>; <a href="./references#CD002190-bbs2-0085" title="NCT01139437. Safety of a live attenuated human parainfluenza virus type 2 (HPIV2) vaccine for adults, children, and infants [AÂ phase I study of the safety and immunogenicity of the recombinant live-attenuated human parainfluenza type 2 virus vaccine, rHPIV2 15C/948L/Î1724Â lot PIV2#109C, delivered as nose drops to adults 18 to 49 years of age, HPIV2-seropositive children 15 to 59 months of age, and HPIV2-seronegative infants and children 6 to 59 months of age]. clinicaltrials.gov/ct2/show/NCT01139437 (first received 8 June 2010). ">NCT01139437</a>; <a href="./references#CD002190-bbs2-0086" title="NCT01254175. Evaluating the safety and immunogenicity of a human parainfluenza type 3 (HPIV3) virus vaccine in infants and children [Phase 1 study to determine the safety, infectivity, immunogenicity and tolerability of 2 doses of live attenuated recombinant cold-passaged (cp) 45 human parainfluenza type 3 virus vaccine, rHPIV3cp45,Â lot PIV3#102A, delivered as nose drops to HPIV3-seronegative infants and children 6 to 36 months of age, at a 6 month interval]. clinicaltrials.gov/ct2/show/NCT01254175 (first received 6 December 2010). ">NCT01254175</a>; <a href="./references#CD002190-bbs2-0087" title="NCT01290419. Safety study of respiratory syncytial virus (RSV)-fusion (F) protein particle vaccine [AÂ phase 1Â randomized, observer-blinded,placebo-controlled trial to evaluate the safety and immunogenicity of a recombinant respiratory syncytial virus f protein particle vaccine in healthy adults]. clinicaltrials.gov/ct2/show/NCT01290419 (first received 7 February 2011). ">NCT01290419</a>; <a href="./references#CD002190-bbs2-0088" title="NCT01475305. Intranasal challenge of healthy adults with respiratory syncytial virus (RSV) [A phase 1 randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of MEDI-557 in healthy adults intranasally challenged with respiratory syncytial virus (RSV)]. clinicaltrials.gov/ct2/show/NCT01475305 (first received 21 November 2011). ">NCT01475305</a>; <a href="./references#CD002190-bbs2-0089" title="NCT01709019. RSV-F vaccine and influenza vaccine co-administration study in the elderly [AÂ phase I randomized, observer-blinded, dose-ranging study to evaluate the immunogenicity and safety of an RSV-F protein nanoparticle vaccine, with or without aluminum adjuvant, and co-administered with a licensed inactivated influenza vaccine, in healthy subjects â¥ 60 years of age]. clinicaltrials.gov/ct2/show/NCT01709019 (first received 17 October 2012). ">NCT01709019</a>; <a href="./references#CD002190-bbs2-0090" title="NCT01852266. Evaluating the safety and immune response to a single dose of a respiratory syncytial virus (RSV) vaccine in RSV-seronegative infants and children [AÂ phase I study of the safety and immunogenicity of a single dose of the recombinant live-attenuated respiratory syncytial virus vaccine RSV cps2,Â lot RSV#005A, delivered as nose drops to RSV-seronegative infants and children 6 to 24 months of age]. clinicaltrials.gov/ct2/show/NCT01852266 (first received 13 May 2013). ">NCT01852266</a>; <a href="./references#CD002190-bbs2-0091" title="NCT01905215. Study to evaluate the safety, reactogenicity and immunogenicity of GlaxoSmithKline (GSK) biologicals' investigational respiratory syncytial virus (RSV) vaccines [An observer-blind study to evaluate the safety, reactogenicity and immunogenicity of GSK biologicals' respiratory syncytial virus (RSV)Â investigationalÂ vaccine (GSK3003891A) in healthy men]. clinicaltrials.gov/ct2/show/NCT01905215 (first received 23 July 2013). ">NCT01905215</a>; <a href="./references#CD002190-bbs2-0092" title="NCT02115815. A study to evaluate the safety of the respiratory syncytial virus vaccine MEDI7510 in older adults [AÂ phase 1a study to evaluate the safety of the respiratory syncytial virus vaccine MEDI7510 in older adults]. clinicaltrials.gov/ct2/show/NCT02115815 (first received 16 April 2014). ">NCT02115815</a>; <a href="./references#CD002190-bbs2-0093" title="NCT02266628. Placebo-controlled study to evaluate the safety and immunogenicity of the RSV-F vaccine in elderly adults [AÂ phase II randomized, observer-blind, placebo-controlled study to evaluate the immunogenicity and safety of respiratory syncytial virus (RSV) F vaccine in healthy elderly subjects and to estimate the incidence rate of medically-attended RSV disease in vaccine and placebo recipients]. clinicaltrials.gov/ct2/show/NCT02266628 (first received 17 October 2014). ">NCT02266628</a>; <a href="./references#CD002190-bbs2-0094" title="NCT02296463. A phase I randomized, observer-blinded, dose-ranging study in healthy subjects 24 to &lt; 72 months of age [AÂ phase I randomized, observer-blinded, dose-ranging study to evaluate the immunogenicity and safety of a respiratory syncytial virus (RSV) recombinant fusion (F) nanoparticle vaccine, with or without aluminum adjuvant, in healthy subjects 24 to &lt;Â 72 months of age]. clinicaltrials.gov/ct2/show/NCT02296463 (first received 20 November 2014). ">NCT02296463</a>; <a href="./references#CD002190-bbs2-0095" title="NCT02419391. Trial to evaluate the safety, tolerability and immunogenicity of the recombinant MVA BNÂ® RSV vaccine [A randomized, single-blind, placebo-controlled phase i trial to evaluate the safety, tolerability and immunogenicity of the recombinant MVA BNÂ® RSV vaccine in healthy adult subjects]. clinicaltrials.gov/ct2/show/NCT02419391 (first received 17 April 2015). ">NCT02419391</a>; <a href="./references#CD002190-bbs2-0096" title="NCT02440035. A study to evaluate the safety, tolerability and immunogenicity of Ad35.RSV.FA2 regimens boosted with Ad26.RSV.FA2 in healthy adult participants [Phase 1, first in human study to evaluate the safety, tolerability and immunogenicity of Ad35.RSV.FA2 regimens boosted with Ad26.RSV.FA2 in healthy adult volunteers]. clinicaltrials.gov/ct2/show/NCT02440035Â  (first received 17 April 2015). ">NCT02440035</a>; <a href="./references#CD002190-bbs2-0097" title="NCT02472548. A study to evaluate the safety and reactogenicity of DPX-RSV(A), a respiratory syncytial virus [AÂ phase I randomized, observer-blind, controlled, dose escalation trial of the safety and tolerability of two intramuscular doses of DPX-RSV(A), a respiratory syncytial virus vaccine containing respiratory syncytial virus (RSV) SHe antigen and a novel adjuvant DepoVaxTM, or SHe a antigen co-administered with aluminum hydroxide, or placebo to healthy adults â¥50-64 years of age]. clinicaltrials.gov/ct2/show/NCT02472548 (first received 16 June 2015). ">NCT02472548</a>; <a href="./references#CD002190-bbs2-0098" title="NCT02479750. Evaluation of ColdZymeÂ® on experimentally induced common cold [Evaluation of ColdZymeÂ® on experimentally induced common coldÂ -Â a double-blind, randomized, placebo-controlled study in healthy volunteers]. clinicaltrials.gov/ct2/show/NCT02479750 (first received 24 June 2015). ">NCT02479750</a>; <a href="./references#CD002190-bbs2-0099" title="NCT02491463. A study to assess the safety, reactogenicity and immunogenicity of GlaxoSmithKline (GSK) biologicals' RSV investigational vaccine (ChAd155-RSV) (GSK3389245A) in healthy adults [A study to evaluate safety, reactogenicity and immunogenicity of GSKÂ biologicals' RSV investigational vaccine based on viral proteins encoded by chimpanzee-derived adenovector (ChAd155-RSV) (GSK3389245A) in healthy adults]. clinicaltrials.gov/ct2/show/NCT02491463 (first received 8 July 2015). ">NCT02491463</a>; <a href="./references#CD002190-bbs2-0100" title="NCT02561871. A study to evaluate the safety, tolerability and immunogenicity of Ad26.RSV.FA2 followed by Ad35.RSV.FA2 in healthy adult volunteers [Phase 1, first in human study to evaluate the safety, tolerability and immunogenicity of Ad26.RSV.FA2Â followed by Ad35.RSV.FA2 in healthy adult volunteers]. clinicaltrials.gov/ct2/show/NCT02561871 (first received 28 September 2015). ">NCT02561871</a>; <a href="./references#CD002190-bbs2-0101" title="NCT02593071. Safety and immunogenicity of the RSV-F vaccine in older adults previously treated with the same vaccine or placebo in the prior year [AÂ phase II randomized, observer-blind, placebo-controlled study to evaluate the immunogenicity and safety of a respiratory syncytial virus (RSV)Â recombinant F nanoparticle vaccine in healthy older adult subjects previously treated with the same vaccine, or placebo, in the prior year; and to estimate the incidence rate of RSV disease and vaccine efficacy in subjects based on their RSV F vaccine experience over two consecutive years]. clinicaltrials.gov/ct2/show/NCT02593071 (first received 30 October 2015). ">NCT02593071</a>; <a href="./references#CD002190-bbs2-0102" title="NCT02601612. Safety and immunogenicity of the RSV D46cpÎM2-2 Vaccine in RSV-seropositive children and RSV-seronegative infants and children [AÂ phase I study of the safety and immunogenicity of a single dose of the live recombinant RSV D46cpÎM2-2 vero grown virus vaccine (lot RSV #008A), delivered as nose drops to RSV-seropositive children 12 to 59 months of age and RSV-seronegative infants and children 6 to 24 months of age]. clinicaltrials.gov/ct2/show/NCT02601612 (first received 10 November 2015). ">NCT02601612</a>; <a href="./references#CD002190-bbs2-0103" title="NCT02624947. A study to determine the safety and efficacy of the RSV F vaccine to protect infants via maternal immunization [AÂ phase 3, randomized, observer-blind, placebo-controlled study to determine the immunogenicity and safety of a respiratory syncytial virus (RSV) F nanoparticle vaccine with aluminum in healthy third-trimester pregnant women; and safety and efficacy of maternally transferred antibodies in preventing rsv disease in their infants]. clinicaltrials.gov/ct2/show/NCT02624947 (first received 9 December 2015). ">NCT02624947</a>; <a href="./references#CD002190-bbs2-0104" title="NCT02794870. Evaluating the infectivity, safety and immunogenicity of a recombinant live-attenuated respiratory syncytial virus vaccine in RSV-seronegative infants 6 to 24 months of age [Phase I placebo-controlled study of the infectivity, safety and immunogenicity of a single dose of a recombinant live-attenuated respiratory syncytial virus vaccine, LID ÎM2-2 1030s,Â lot RSV#010A, delivered as nose drops to RSV-seronegative infants 6 to 24 months of age]. clinicaltrials.gov/ct2/show/NCT02794870 (first received 9 June 2016). ">NCT02794870</a>; <a href="./references#CD002190-bbs2-0105" title="NCT02830932. Dose-ranging trial of safety &amp; immunogenicity of an oral adenoviral-vector based RSV vaccine (VXA-RSV-f) [AÂ phase 1, randomized, double-blind, placebo-controlled, dose-ranging trial to determine the safety and immunogenicity of an adenoviral-vector based respiratory syncytial virus (RSV) F protein vaccine (VXA-RSV-f) expressing protein F and dsRNA adjuvant administered orally to healthy volunteers]. clinicaltrials.gov/ct2/show/NCT02830932 (first received 13 July 2016). ">NCT02830932</a>; <a href="./references#CD002190-bbs2-0106" title="NCT02864628. RSV-MVA-BN vaccine phase I trial, intranasal application in adults [A partially randomized, partly placebo controlled phase i trial to evaluate the safety, tolerability and immunogenicity of the recombinant MVA-BNÂ® RSV vaccine after intranasal and intramuscular administration]. clinicaltrials.gov/ct2/show/NCT02864628 (first received 12 August 2016). ">NCT02864628</a>; <a href="./references#CD002190-bbs2-0107" title="NCT02873286. RSV-MVA-BN vaccine phase II trial in â¥ 55 year old adults [A randomized, single-blind, placebo controlled, dose-ranging phase II trial in â¥ 55 year old adults to evaluate the safety and immunogenicity of the recombinant MVA-BN-RSVÂ vaccine]. clinicaltrials.gov/ct2/show/NCT02873286 (first received 19 August 2016). ">NCT02873286</a>; <a href="./references#CD002190-bbs2-0108" title="NCT02890381. Evaluating the infectivity, safety and immunogenicity of a recombinant live-attenuated respiratory syncytial virus vaccine (RSV LID cp ÎM2-2) in RSV-seronegative infants 6 to 24 months of age [Phase I placebo-controlled study of the infectivity, safety and immunogenicity of a single dose of a recombinant live-attenuated respiratory syncytial virus vaccine, LID cp ÎM2-2,Â lot RSV#009B, delivered as nose drops to RSV-seronegative infants 6 to 24 months of age]. clinicaltrials.gov/ct2/show/NCT02890381 (first received 7 September 2016). ">NCT02890381</a>; <a href="./references#CD002190-bbs2-0109" title="NCT02926430. A study to evaluate the safety, tolerability and immunogenicity of two vaccinations of Ad26.RSV.preF one year apart in adults aged 60 years and older in stable health [A randomized, double-blind, first-in-human phase 1 study to evaluate the safety, tolerability and immunogenicity of two vaccinations of Ad26.RSV.preF one year apart in adults aged 60 years and older in stable health]. clinicaltrials.gov/ct2/show/NCT02926430 (first received 6 October 2016). ">NCT02926430</a>; <a href="./references#CD002190-bbs2-0110" title="NCT02952339. Evaluating the infectivity, safety and immunogenicity of a recombinant live-attenuated respiratory syncytial virus vaccine (RSV LID cp ÎM2-2) in RSV-seronegative infants 6 to 24 months of age [Phase I placebo-controlled study of the infectivity, safety and immunogenicity of a single dose of a recombinant live-attenuated respiratory syncytial virus vaccine, LID ÎM2-2 1030s,Â lot RSV#010A, delivered as nose drops to RSV-seronegative infants and children 6 to 24 months of age]. clinicaltrials.gov/ct2/show/NCT02952339 (first received 2 November 2016). ">NCT02952339</a>; <a href="./references#CD002190-bbs2-0111" title="NCT03026348. Safety and immunogenicity study to evaluate single- or two-dose regimens of RSV F vaccine with and without aluminum phosphate or Matrix-M1â¢ adjuvants in clinically-stable older adults. clinicaltrials.gov/ct2/show/NCT03026348 (first received 20 January 2017). ">NCT03026348</a>; <a href="./references#CD002190-bbs2-0112" title="NCT03049488. Dose, safety, tolerability and immunogenicity of a stabilized prefusion RSV F subunit protein vaccine, VRC-RSVRGP084-00-VP (DS-Cav1), alone or with alum adjuvant, in healthy adults [VRC 317: a phase I randomized, open-label clinical trial to evaluate dose, safety, tolerability and immunogenicity of a stabilized prefusion RSV F subunit protein vaccine, VRC-RSVRGP084-00-VP (DS-Cav1), alone or with alum adjuvant, in healthy adults]. clinicaltrials.gov/ct2/show/NCT03049488 (first received 10 February 2017). ">NCT03049488</a>; <a href="./references#CD002190-bbs2-0113" title="NCT03191383. A study to evaluate the safety, reactogenicity and immunogenicity of the GlaxoSmithKline (GSK) biologicals' respiratory syncytial virus (RSV) investigational vaccine (GSK3003891A) in healthy pregnant women and infants born to vaccinated mothers [An observer-blind study to assess the safety, reactogenicity and immunogenicity of GSK biologicals' investigational RSVÂ vaccine (GSK3003891A), in healthy pregnant women and infants born to vaccinated mothers]. clinicaltrials.gov/ct2/show/NCT03191383 (first received 19 June 2017). ">NCT03191383</a>; <a href="./references#CD002190-bbs2-0114" title="NCT03303625. A study to evaluate the safety, tolerability and immunogenicity of an investigational RSV vaccine candidate (Ad26.RSV.preF) in adults 18 to 50 years of age, and RSV-seropositive toddlers 12 to 24 months of age [A randomized, double-blind, phase 1/2a study to evaluate the safety, tolerability and immunogenicity of Ad26.RSV.preF in adults 18 to 50 years of age, RSV-seropositive toddlers 12 to 24 months of age]. clinicaltrials.gov/ct2/show/NCT03303625 (first received 6 October 2017). ">NCT03303625</a>; <a href="./references#CD002190-bbs2-0115" title="NCT03334695. An exploratory study to evaluate the prophylactic efficacy of a single immunization of Ad26.RSV.preF against respiratory syncytial virus infection in a virus challenge model in healthy 18 to 50 year-old adults [An exploratory, phase 2a, randomized, double-blind, placebo-controlled study to evaluate the prophylactic efficacy of a single immunization of Ad26.RSV.preF against respiratory syncytial virus infection in a virus challenge model in healthy 18 to 50 year-old adults]. clinicaltrials.gov/ct2/show/NCT03334695 (first received 17 November 2017). ">NCT03334695</a>; <a href="./references#CD002190-bbs2-0116" title="NCT03392389. Safety, reactogenicity, and immunogenicity of mRNA-1653 in healthy adults [A phase 1, randomized, observer-blind, placebo-controlled, dose-ranging study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1653, a combined human metapneumovirus and human parainfluenza virus type 3 vaccine, when administered to healthy adult]. clinicaltrials.gov/ct2/show/NCT03392389 (first received 8 January 2018). ">NCT03392389</a>; <a href="./references#CD002190-bbs2-0117" title="NCT03403348. A first-in-human study of orally administered JNJ-64417184 to evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending doses, and the antiviral activity of multiple doses in a respiratory syncytial virus (RSV) challenge study in healthy participants [A randomized, double-blind, placebo-controlled, first-in-human, 6-part study of orally administered JNJ-64417184 to evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending doses, and the antiviral activity of multiple doses in a respiratory syncytial virus (RSV) challenge study in healthy subjects]. clinicaltrials.gov/ct2/show/NCT03403348 (first received 18 January 2018). ">NCT03403348</a>; <a href="./references#CD002190-bbs2-0118" title="NCT03473002. A safety and immunogenicity study of intranasal sendai virus vectored respiratory syncytial virus (SeVRSV) vaccine in healthy adults [AÂ phase I double-blind placebo controlled trial to evaluate the safety and immunogenicity of intranasal sendai virus vectored respiratory syncytial virus (SeVRSV) vaccine in healthy adults]. clinicaltrials.gov/ct2/show/NCT03473002 (first received 21 March 2018). ">NCT03473002</a>; <a href="./references#CD002190-bbs2-0119" title="NCT03572062. A study to evaluate the safety and immunogenicity of an adjuvanted RSV vaccine in healthy older adults [A phase 1/2, placebo-controlled, randomized, observer-blind, dose-finding, first-in-human study to describe the safety, tolerability, and immunogenicity of an adjuvanted respiratory syncytial virus (RSV) vaccine in healthy older adults]. clinicaltrials.gov/ct2/show/NCT03572062 (first received 28 June 2018). ">NCT03572062</a>; <a href="./references#CD002190-bbs2-0120" title="NCT03674177. A study to evaluate different dose levels of GlaxoSmithKline (GSK) biologicals' investigational respiratory syncytial virus (RSV) vaccine (GSK3888550A), based on the vaccine safety and the antibodies (body defences) produced following vaccine administration [A study to evaluate the safety, reactogenicity and immunogenicity of GSK biologicals' investigational unadjuvanted RSV maternal vaccine compared to placebo when administered to healthy non-pregnant women]. clinicaltrials.gov/ct2/show/NCT03674177 (first received 17 September 2018). ">NCT03674177</a>; <a href="./references#CD002190-bbs2-0121" title="NCT03814590. A study to assess the safety, reactogenicity and immune response of GlaxoSmithKline (GSK) biologicals' investigational respiratory syncytial virus (RSV) vaccine (GSK3844766A) in older adults [Phase I/II, observer-blind, safety, reactogenicity and immunogenicity study of GSK biologicals' respiratory syncytial virus (RSV)Â vaccine GSK3844766A in subjects aged 18-40 or 60-80 years]. clinicaltrials.gov/ct2/show/NCT03814590 (first received 24 January 2019). ">NCT03814590</a>; <a href="./references#CD002190-bbs2-0122" title="NCT04071158. A study of a RSV vaccines when given together with TDAP in healthy non-pregnant women aged between 18 to 49 years [A phase 2b, placebo-controlled, randomized, observer-blind study to evaluate the safety, tolerability, and immunogenicity of a respiratory syncytial virus (RSV) vaccine when administered concomitantly with tetanus, diphtheria, and acellular pertussis vaccine (TDAP) in healthy nonpregnant women 18 through 49 years of age]. clinicaltrials.gov/ct2/show/NCT04071158 (first received 28 August 2019). ">NCT04071158</a>; <a href="./references#CD002190-bbs2-0123" title="NCT04086472. Phase 2a respiratory syncytial virus (RSV) human challenge study of MK-1654 in healthy participants (MK-1654-005) [A phase 2a double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of MK-1654 in healthy participants inoculated with experimental respiratory syncytial virus]. clinicaltrials.gov/ct2/show/NCT04086472 (first received 11 September 2019). ">NCT04086472</a>; <a href="./references#CD002190-bbs2-0124" title="NCT04752644. Phase 2a study of MVA-BN-RSV vaccination and RSV challenge in healthy adults [A phase 2a, randomised, double-blinded, placebo-controlled study to assess the safety, immunogenicity and efficacy of the recombinant MVA-BNÂ®-RSV vaccine against respiratory syncytial virus infection in the virus challenge model in healthy adult participants]. clinicaltrials.gov/ct2/show/NCT04752644 (first received 12 February 2021). ">NCT04752644</a>; <a href="./references#CD002190-bbs2-0125" title="NTR7173. Clinical study to evaluate safety, tolerability and effects on the immune system of a common cold vaccine in healthy adults [Randomised, double-blind, placebo-controlled study to evaluate the safety, tolerability, immunogenicity and shedding of live-attenuated RSV vaccine in healthy adults]. www.who.int/trialsearch/Trial2.aspx?TrialID=NTR7173 (first received 18 May 2018). ">NTR7173</a>; <a href="./references#CD002190-bbs2-0127" title="PhilpottE , EnglundJ , TielschJ , KatzJ , KhatryS , LeclerqSC , et al. Effect of febrile rhinovirus illness during pregnancy on adverse birth outcomes in Nepal. Open Forum Infectious Diseases2016;3(Suppl 1):1751. [DOI: 10.1093/ofid/ofw194.131]">Philpott 2016</a>; <a href="./references#CD002190-bbs2-0128" title="PhilpottEK , EnglundJA , KatzJ , TielschJ , KhatryS , LeClerqSC , et al. Febrile rhinovirus illness during pregnancy is associated with low birth weight in Nepal. Open Forum Infectious Diseases2017;4(2):ofx073. [DOI: 10.1093/ofid/ofx073]">Philpott 2017</a>; <a href="./references#CD002190-bbs2-0133" title="RuckwardtT , MorabitoK , PhungE , CrankM , CostnerP , HolmanL , et al. Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial. Lancet Respiratory Medicine2021;9(10):1111-20. [DOI: 10.1016/S2213-2600(21)00098-9] [PMID: 33864736]">Ruckwardt 2021</a>; <a href="./references#CD002190-bbs2-0134" title="SadoffJ , De PaepeE , DeVincenzoJ , GymnopoulouE , MentenJ , MurrayB , et al. Prevention of respiratory syncytial virus infection in healthy adults by a single immunization of Ad26.RSV.preF in a human challenge study. Journal of Infectious Diseases2022;226(3):396-406. [DOI: 10.1093/infdis/jiab003] [PMID: 33400792]">Sadoff 2021a</a>; <a href="./references#CD002190-bbs2-0135" title="SadoffJ , De PaepeE , HaazenW , OmoruyiE , BastianAR , ComeauxC . Safety and immunogenicity of the Ad26.RSV.preF investigational vaccine coadministered with an influenza vaccine in older adults. Journal of Infectious Diseases2021;223(4):699-708. [DOI: 10.1093/infdis/jiaa409] [PMID: 32851411]">Sadoff 2021b</a>; <a href="./references#CD002190-bbs2-0136" title="SamyN , ReichhardtD , SchmidtD , ChenLM , SilbernaglG , VidojkovicS , et al. Safety and immunogenicity of novel modified vaccinia Ankara-vectored RSV vaccine: a randomized phase I clinical trial. Vaccine2020;38(11):2608-19. [DOI: 10.1016/j.vaccine.2020.01.055]">Samy 2020</a>; <a href="./references#CD002190-bbs2-0137" title="Scaggs HuangF , BernsteinDI , SlobodKS , PortnerA , TakimotoT , RussellCJ , et al. Safety and immunogenicity of an intranasal sendai virus-based vaccine for human parainfluenza virus type I and respiratory syncytial virus (SeVRSV) in adults. Human Vaccines &amp; Immunotherapeutics2021;17(2):554-9. [DOI: 10.1080/21645515.2020.1779517]">Scaggs Huang 2021</a>; <a href="./references#CD002190-bbs2-0138" title="SchwarzTF , McPheeRA , LaunayO , Leroux-RoelsG , TalliJ , PicciolatoM , et al. Immunogenicity and safety of 3 formulations of a respiratory syncytial virus candidate vaccine in non-pregnant women: a phase II, randomized trial. Journal of Infectious Diseases2019;220(11):1816-25. [DOI: 10.1093/infdis/jiz395]">Schwarz 2019</a>; <a href="./references#CD002190-bbs2-0139" title="ShakibJH , VarnerMW , FiuzaM , TrenholmeAA , BaquiA , FrechS , et al. Immunoglobulin A, immunoglobulin G, and neutralizing antibodies to respiratory syncytial virus increase in human milk following immunization with an RSV F protein vaccine. International Journal of Stroke2019;221(6):669-70. [DOI: 10.1016/j.ajog.2019.10.080]">Shakib 2019</a>; <a href="./references#CD002190-bbs2-0140" title="ShawC , LeeH , KnightlyC , KalidindiS , ZaksT , SmolenovI , et al. Phase 1 trial of an mRNA-based combination vaccine against HMPV and PIV3. Open Forum Infectious Diseases2019;6(Suppl 2):S970. [DOI: 10.1093/ofid/ofz360.2431]">Shaw 2019</a>; <a href="./references#CD002190-bbs2-0142" title="SwamyGK , MunozFM , PolackF , MadhiSA , TrenholmeAA , SimoesEA , et al. Safety of third trimester immunization with a respiratory syncytial virus F protein vaccine and protection of infants over the first 180 days of life against all-cause lower respiratory tract infection. American Journal of Obstetrics &amp; Gynecology2019;221(6):670. [DOI: 10.1016/j.ajog.2019.10.081]">Swamy 2019</a>; <a href="./references#CD002190-bbs2-0146" title="Van Der PlasJ , VerdijkP , Van BrummelenE , RoestenbergM , BurggraafJ , KamerlingI . First-in-human, randomized study to assess the safety, tolerability, immunogenicity, and shedding of a live attenuated respiratory syncytial virus vaccine. British Journal of Clinical Pharmacology2020;86(6):1189-90. [DOI: 10.1111/bcp.14266]">Van Der Plas 2020</a>; <a href="./references#CD002190-bbs2-0147" title="VerdijkP , van derPlasJL , vanBrummelenE , JeeningaRE , deHaanC , RoestenbergM , et al. First-in-human administration of a live-attenuated RSV vaccine lacking the G-protein assessing safety, tolerability, shedding and immunogenicity: a randomized controlled trial. Vaccine2020;38(39):6088-95. [DOI: 10.1016/j.vaccine.2020.07.029] [PMID: 32718816]">Verdijk 2020</a>; <a href="./references#CD002190-bbs2-0150" title="WilliamsK , BastianAR , FeldmanRA , OmoruyiE , dePaepeE , HendriksJ , et al. Phase 1 safety and immunogenicity study of a respiratory syncytial virus vaccine with an adenovirus 26 vector encoding prefusion F (Ad26.RSV.preF) in adults aged â¥ 60 years. Journal of Infectious Diseases2020;222(6):979-88. [DOI: 10.1093/infdis/jiaa193] [PMID: 32320465]">Williams 2020</a>; <a href="./references#CD002190-bbs2-0153" title="YuJ , PowersJH , ValloD , FalloonJ . Evaluation of efficacy endpoints for a phase IIb study of a respiratory syncytial virus vaccine in older adults using patient-reported outcomes with laboratory confirmation. Value Health2020;23(2):227-35. [DOI: 10.1016/j.jval.2019.09.2747]">Yu 2020</a>). We identified 13 ongoing studies (<a href="./references#CD002190-bbs2-0154" title="NCT01893554. Evaluating the safety and immune response to a single dose of a respiratory syncytial virus (RSV) vaccine in infants and children [A phase I study of the safety and immunogenicity of a single dose of the recombinant live-attenuated respiratory syncytial virus vaccine RSV ÎNS2 Î1313 I1314L, lot RSV#006A, delivered as nose drops to RSV-seropositive children 12 to 59 months of age, RSV-seronegative infants and children 6 to 24 months of age, and infants 4 to 6 months of age]. clinicaltrials.gov/ct2/show/NCT01893554 (first received 9 July 2013). ">NCT01893554</a>; <a href="./references#CD002190-bbs2-0155" title="NCT03387137. Evaluating the infectivity, safety, and immunogenicity of a respiratory syncytial virus vaccine (RSV 6120/âNS2/1030s) in RSV-seropositive children and RSV-seronegative infants and children [PhaseÂ I placebo-controlled study of the infectivity, safety and immunogenicity of a single dose of a recombinant live-attenuatedÂ respiratory syncytial virus Â vaccine, 6120/âNS2/1030s, lot RSV#012A, delivered as nose drops toÂ RSV-seropositive children 12 to 59 months of age andÂ RSV-seronegative infants and children 6 to 24 months of age]. clinicaltrials.gov/ct2/show/NCT03387137 (first received 29 December 2017). ">NCT03387137</a>; <a href="./references#CD002190-bbs2-0156" title="NCT03422237. Evaluating the infectivity, safety, and immunogenicity of the recombinant live-attenuated respiratory syncytial virus (RSV) vaccines RSV ÎNS2/Î1313/I1314L or RSV 276 in RSV-seronegative infants and children 6 to 24 months of age [RandomizedÂ phase I study of the infectivity, safety, and immunogenicity of a single dose of the recombinant live-attenuated respiratory syncytial virus (RSV)Â vaccines RSV ÎNS2/Î1313/I1314L or RSV 276 orÂ placebo, delivered as nose drops to RSV-seronegative infants and children 6 to 24 months of age]. clinicaltrials.gov/ct2/show/NCT03422237 (first received 5 February 2018). ">NCT03422237</a>; <a href="./references#CD002190-bbs2-0157" title="NCT03596801. Evaluating the infectivity, safety and immunogenicity of respiratory syncytial virus vaccines, RSV 6120/âNS1 and RSV 6120/F1/G2/âNS1, in RSV-seropositive children and RSV-seronegative infants and children [Phase I placebo-controlled study of the infectivity, safety and immunogenicity of a single dose of a recombinant live-attenuated respiratory syncytial virusÂ vaccine, RSV 6120/âNS1, lot RSV#018A, or RSV 6120/F1/G2/âNS1, lot RSV#016A, delivered as nose drops to RSV-seropositive children 12 to 59 months of age and RSV-seronegative infants and children 6 to 24 months of age]. clinicaltrials.gov/ct2/show/NCT03596801 (first received 24 July 2018). ">NCT03596801</a>; <a href="./references#CD002190-bbs2-0158" title="NCT03916185. Safety and immunogenicity of a single dose of the recombinant live-attenuated respiratory syncytial virus (RSV) vaccines RSV ÎNS2/Î1313/I1314L, RSV 6120/ÎNS2/1030s, RSV 276 or placebo, delivered as nose drops to RSV-seronegative children 6 to 24 months of age [RandomizedÂ phase I/II study of the safety and immunogenicity of a single dose of the recombinant live-attenuated respiratory syncytial virus (RSV) vaccines RSV ÎNS2/Î1313/I1314L, RSV 6120/ÎNS2/1030s, RSV 276 or placebo, delivered as nose drops to RSV-seronegative children 6 to 24 months of age]. clinicaltrials.gov/ct2/show/NCT03916185Â  (first received 16 April 2019). ">NCT03916185</a>; <a href="./references#CD002190-bbs2-0159" title="NCT04032093. A phase 2B placebo-controlled, randomized study of a respiratory syncytial virus (RSV) vaccine in pregnant women [AÂ phase 2B, randomized, placebo-controlled, observer-blinded trial to evaluate the safety, tolerability, and immunogenicity of a respiratory syncytial virus (RSV) vaccine in pregnant women 18 through 49 years of age and their infants]. clinicaltrials.gov/ct2/show/NCT04032093 (first received 25 July 2019). ">NCT04032093</a>; <a href="./references#CD002190-bbs2-0160" title="NCT04126213. Study of safety, reactogenicity and immunogenicity of GlaxoSmithKline's (GSK) respiratory syncytial virus (RSV) maternal unadjuvanted vaccine in healthy pregnant women (aged 18 to 40 years) and their infants [AÂ phase II, randomised, observer-blind, placebo controlled multi-country study to assess the safety, reactogenicity and immunogenicity of a single intramuscular dose of GSK biologicals' investigational RSV maternal unadjuvanted vaccine (GSK3888550A), in healthy pregnant women aged 18 to 40 years and infants born to vaccinated mothers]. clinicaltrials.gov/ct2/show/NCT04126213 (first received 15 October 2019). ">NCT04126213</a>; <a href="./references#CD002190-bbs2-0161" title="NCT04138056. A study of a vaccine against respiratory syncytial virus (RSV) when given alone and together with a vaccine against diphtheria, pertussis and tetanus (Tdap) viruses followed by a 2nd dose of the RSV vaccine to healthy non-pregnant women [AÂ phase II study of a primary dose of investigational RSV maternal vaccine, given alone or with Boostrix, with a 2nd dose investigational RSV maternal vaccine]. clinicaltrials.gov/ct2/show/NCT04138056 (first received 24 October 2019). ">NCT04138056</a>; <a href="./references#CD002190-bbs2-0162" title="NCT04681833. Safety and efficacy of BARS13 in the elderly [A randomised, double-blind, placebo-controlled, dose-ranging phase II study in 60 to 80-year-old adults to assess the safety and immunogenicity of BARS13]. clinicaltrials.gov/ct2/show/NCT04681833 (first received 23 December 2020). ">NCT04681833</a>; <a href="./references#CD002190-bbs2-0163" title="NCT04732871. Immunogenicity, safety, reactogenicity and persistence of an investigational respiratory syncytial virus (RSV) vaccine in adults aged 60 years and above [A phase 3, randomized, open-label, multi-country study to evaluate the immunogenicity, safety, reactogenicity and persistence of a single dose of the RSVPreF3 OA investigational vaccine and different revaccination schedules in adults aged 60 years and above]. clinicaltrials.gov/ct2/show/NCT04732871 (first received 1 February 2021). ">NCT04732871</a>; <a href="./references#CD002190-bbs2-0164" title="NCT04980391. A study on the safety and immune response to an unadjuvanted RSV maternal vaccine, in high-risk pregnant women aged 15 to 49 years and infants born to the vaccinated mothers [A phase III, double-blind, randomized, placebo-controlled study to evaluate the safety, reactogenicity and immune response of a single intramuscular dose of unadjuvanted RSV maternal vaccine, in high-risk pregnant women aged 15 to 49 years and infants born to the vaccinated mother]. clinicaltrials.gov/ct2/show/NCT04980391 (first received July 28 2021). ">NCT04980391</a>; <a href="./references#CD002190-bbs2-0165" title="NCT05127434. A study to evaluate the safety and efficacy of mRNA-1345 vaccine targeting respiratory syncytial virus (RSV) in adults â¥60 years of age [A phase 2/3, randomized, observer-blind, placebo-controlled study to evaluate the safety and efficacy of mRNA-1345, an mRNA vaccine targeting respiratory syncytial virus (RSV), in adults â¥60 years of age]. clinicaltrials.gov/ct2/show/NCT05127434 (first received 19 November 2021). ">NCT05127434</a>; <a href="./references#CD002190-bbs2-0166" title="NCT05238025. Phase 3 MVA-BN-RSV vaccine efficacy trial [A randomized, double-blind, phase 3 trial to assess clinical efficacy, safety and reactogenicity of the recombinant MVA-BNÂ® -RSV vaccine in adults â¥60 years of age]. clinicaltrials.gov/ct2/show/NCT05238025 (first received 14 February 2022). ">NCT05238025</a>). We contacted the authors of the ongoing trials; however, no preliminary results have been shared with us.Â  </p> </section> </section> <section id="CD002190-sec-0044"> <h3 class="title">Risk of bias in included studies</h3> <p><a href="./references#CD002190-bbs2-0001" title="GriffinJP , GreenbergBH . Live and inactivated adenovirus vaccines. Clinical evaluation of efficacy in prevention of acute respiratory disease. Archives of Internal Medicine1970;125(6):981-6. [PMID: 4378136]">Griffin 1970</a> had overall low methodological quality. See <a href="#CD002190-fig-0003">Figure 3</a> and <a href="#CD002190-fig-0004">Figure 4</a>. </p> <div class="figure" id="CD002190-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages." data-id="CD002190-fig-0003" src="/cdsr/doi/10.1002/14651858.CD002190.pub6/media/CDSR/CD002190/image_n/nCD002190-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages. </p> </div> </div> </div> <div class="figure" id="CD002190-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for the included study." data-id="CD002190-fig-0004" src="/cdsr/doi/10.1002/14651858.CD002190.pub6/media/CDSR/CD002190/image_n/nCD002190-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for the included study. </p> </div> </div> </div> <section id="CD002190-sec-0045"> <h4 class="title">Allocation</h4> <p>We assessed <a href="./references#CD002190-bbs2-0001" title="GriffinJP , GreenbergBH . Live and inactivated adenovirus vaccines. Clinical evaluation of efficacy in prevention of acute respiratory disease. Archives of Internal Medicine1970;125(6):981-6. [PMID: 4378136]">Griffin 1970</a> as at unclear risk of bias for random sequence generation and allocation concealment as inadequate information prevented a judgement for this domain. </p> </section> <section id="CD002190-sec-0046"> <h4 class="title">Blinding</h4> <p>We assessedÂ <a href="./references#CD002190-bbs2-0001" title="GriffinJP , GreenbergBH . Live and inactivated adenovirus vaccines. Clinical evaluation of efficacy in prevention of acute respiratory disease. Archives of Internal Medicine1970;125(6):981-6. [PMID: 4378136]">Griffin 1970</a>Â as at low risk of bias for blinding of participants and personnel and blinding of outcome assessment.Â  </p> </section> <section id="CD002190-sec-0047"> <h4 class="title">Incomplete outcome data</h4> <p>We assessedÂ <a href="./references#CD002190-bbs2-0001" title="GriffinJP , GreenbergBH . Live and inactivated adenovirus vaccines. Clinical evaluation of efficacy in prevention of acute respiratory disease. Archives of Internal Medicine1970;125(6):981-6. [PMID: 4378136]">Griffin 1970</a>Â as at low risk of attrition bias as there were no losses. </p> </section> <section id="CD002190-sec-0048"> <h4 class="title">Selective reporting</h4> <p>We assessed <a href="./references#CD002190-bbs2-0001" title="GriffinJP , GreenbergBH . Live and inactivated adenovirus vaccines. Clinical evaluation of efficacy in prevention of acute respiratory disease. Archives of Internal Medicine1970;125(6):981-6. [PMID: 4378136]">Griffin 1970</a>Â as at unclear risk of reporting bias. The study protocol was not available, but it was clear that the published reports include all expected outcomes. However, some of the outcomes were described in a narrative fashion and did not specify incidence for each group. </p> </section> <section id="CD002190-sec-0049"> <h4 class="title">Other potential sources of bias</h4> <p>We assessedÂ <a href="./references#CD002190-bbs2-0001" title="GriffinJP , GreenbergBH . Live and inactivated adenovirus vaccines. Clinical evaluation of efficacy in prevention of acute respiratory disease. Archives of Internal Medicine1970;125(6):981-6. [PMID: 4378136]">Griffin 1970</a>Â as at unclear risk of other bias. The baseline characteristics of participants were not described, and there was no detailed information relating to assessment of selection bias, preventing an evaluation of whether both groups were comparable. </p> </section> </section> <section id="CD002190-sec-0050"> <h3 class="title" id="CD002190-sec-0050">Effects of interventions</h3> <p>See: <a href="./full#CD002190-tbl-0001"><b>Summary of findings 1</b> Virus vaccines compared to placebo for preventing the common cold in healthy people</a> </p> <p>Our results are based on one RCT with 2307 healthy people, which we assessed as providing very lowâcertainty evidence (<a href="./references#CD002190-bbs2-0001" title="GriffinJP , GreenbergBH . Live and inactivated adenovirus vaccines. Clinical evaluation of efficacy in prevention of acute respiratory disease. Archives of Internal Medicine1970;125(6):981-6. [PMID: 4378136]">Griffin 1970</a>). SeeÂ <a href="./full#CD002190-tbl-0001">summary of findings Table 1</a>. </p> <section id="CD002190-sec-0051"> <h4 class="title">Primary outcomes</h4> <section id="CD002190-sec-0052"> <h5 class="title">1. Incidence of the common cold</h5> <p>We do not know if there is a difference between the adenovirus vaccine and placebo in reducing the incidence of the common cold (risk ratio 0.95, 95% confidence interval 0.45 to 2.02; 1 RCT, 2307 participants, 27 events; <a href="./references#CD002190-fig-0005" title="">Analysis 1.1</a>) (<a href="./references#CD002190-bbs2-0001" title="GriffinJP , GreenbergBH . Live and inactivated adenovirus vaccines. Clinical evaluation of efficacy in prevention of acute respiratory disease. Archives of Internal Medicine1970;125(6):981-6. [PMID: 4378136]">Griffin 1970</a>). We downgraded the certainty of the evidence to very low due to unclear risk of bias; indirectness because the population of this study was only young and healthy men; and imprecision because confidence intervals were wide, and the number of events was low. </p> </section> <section id="CD002190-sec-0053"> <h5 class="title">2. Vaccine safety</h5> <p><a href="./references#CD002190-bbs2-0001" title="GriffinJP , GreenbergBH . Live and inactivated adenovirus vaccines. Clinical evaluation of efficacy in prevention of acute respiratory disease. Archives of Internal Medicine1970;125(6):981-6. [PMID: 4378136]">Griffin 1970</a>Â reported that there were no differences in adverse events between live vaccine preparation and placebo. We downgraded the certainty of the evidence to very low due to unclear risk of bias; indirectness because the population of this study was only young men; and imprecision because confidence intervals were wide, and the number of events was low. </p> </section> <section id="CD002190-sec-0054"> <h5 class="title">3. Mortality</h5> <p><a href="./references#CD002190-bbs2-0001" title="GriffinJP , GreenbergBH . Live and inactivated adenovirus vaccines. Clinical evaluation of efficacy in prevention of acute respiratory disease. Archives of Internal Medicine1970;125(6):981-6. [PMID: 4378136]">Griffin 1970</a>Â did not assess either vaccineârelated or allâcause mortality. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD002190-sec-0055" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD002190-sec-0055"></div> <section id="CD002190-sec-0056"> <h3 class="title" id="CD002190-sec-0056">Summary of main results</h3> <p>One RCT met our inclusion criteriaÂ (<a href="./references#CD002190-bbs2-0001" title="GriffinJP , GreenbergBH . Live and inactivated adenovirus vaccines. Clinical evaluation of efficacy in prevention of acute respiratory disease. Archives of Internal Medicine1970;125(6):981-6. [PMID: 4378136]">Griffin 1970</a>). The incidence of the common cold inÂ <a href="./references#CD002190-bbs2-0001" title="GriffinJP , GreenbergBH . Live and inactivated adenovirus vaccines. Clinical evaluation of efficacy in prevention of acute respiratory disease. Archives of Internal Medicine1970;125(6):981-6. [PMID: 4378136]">Griffin 1970</a>Â was very low, probably due to the fact that only cases resulting in admission to the medical dispensary or hospital were included. Furthermore, the trial authors stated that more common cold cases were diagnosed incidentally when people were hospitalised for other causes, therefore mild cases of illness were not included. </p> <p>Critical appraisal ofÂ <a href="./references#CD002190-bbs2-0001" title="GriffinJP , GreenbergBH . Live and inactivated adenovirus vaccines. Clinical evaluation of efficacy in prevention of acute respiratory disease. Archives of Internal Medicine1970;125(6):981-6. [PMID: 4378136]">Griffin 1970</a>Â did not support the use of any vaccine for preventing the common cold in healthy people. We did not find significant differences in the incidence of the common cold in people treated with adenovirus vaccines compared with placebo.Â <a href="./references#CD002190-bbs2-0001" title="GriffinJP , GreenbergBH . Live and inactivated adenovirus vaccines. Clinical evaluation of efficacy in prevention of acute respiratory disease. Archives of Internal Medicine1970;125(6):981-6. [PMID: 4378136]">Griffin 1970</a>Â did not evaluate main clinical outcomes such as mortality related to the vaccine. No differences in adverse events were reported. The relative effect of any of the vaccines for viruses that cause the common cold remains unclear. </p> </section> <section id="CD002190-sec-0057"> <h3 class="title" id="CD002190-sec-0057">Overall completeness and applicability of evidence</h3> <p>The included trial did not detect statistically significant differences between treatment groups (<a href="./references#CD002190-bbs2-0001" title="GriffinJP , GreenbergBH . Live and inactivated adenovirus vaccines. Clinical evaluation of efficacy in prevention of acute respiratory disease. Archives of Internal Medicine1970;125(6):981-6. [PMID: 4378136]">Griffin 1970</a>). </p> <p>When considering such neutral results, it is important to keep in mind that 'absence of evidence' is not 'evidence of absence' (<a href="./references#CD002190-bbs2-0169" title="AldersonP . Absence of evidence is not evidence of absence. BMJ2004;328(7438):476-7. [DOI: 10.1136/bmj.328.7438.476] [PMID: 14988165]">Alderson 2004</a>;Â <a href="./references#CD002190-bbs2-0172" title="AltmanDG , BlandJM . Absence of evidence is not evidence of absence. BMJ1995;311(7003):485. [PMID: 7647644]">Altman 1995</a>;Â <a href="./references#CD002190-bbs2-0272" title="WesterterpKR . Absence of evidence is no evidence for absence of the phenomenon. American Journal of Clinical Nutrition2020;112(3):501-2. [DOI: 10.1093/ajcn/nqaa165] [PMID: 32584964]">Westerterp 2020</a>). The fact that this review did not detect any differences between intervention groups does not imply that placebo and adenovirus vaccine have the same effect on preventing the common cold. </p> <p>The first possible explanation for not detecting any differences between intervention groups could be the lack of an appropriate sample size (<a href="./references#CD002190-bbs2-0198" title="GreenSB . Design of randomized trials. Epidemiologic Reviews2002;24(1):4-11. [PMID: 12119855]">Green 2002</a>;Â <a href="./references#CD002190-bbs2-0255" title="SchulzKF , ChalmersI , HayesRJ , AltmanDG . Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA1995;273(5):408-12. [PMID: 7823387]">Schulz 1995</a>), which resulted in small differences in the incidence of the common cold and few events in the comparison groups. A remarkable paper fromÂ <a href="./references#CD002190-bbs2-0190" title='FreimanJA , ChalmersTC , Smith H Jr, KueblerRR . The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 "negative" trials. New England Journal of Medicine1978;299(13):690-4. [PMID: 355881]'>Freiman 1978</a>Â suggested that "many of the therapies labelled as 'no different from control' in trials using inadequate samples, have not received a fair test" and that "concern for the probability of missing an important therapeutic improvement because of small sample sizes deserves more attention in the planning of clinical trials".Â Moreover,Â most trials with negative results usually have insufficiently large sample sizes to detect at least 50% relative difference (<a href="./references#CD002190-bbs2-0230" title="MoherD , PhamB , JonesA , CookDJ , JadadAR , MoherM , et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?Lancet1998;352(9128):609-13. [PMID: 9746022]">Moher 1998</a>;Â <a href="./references#CD002190-bbs2-0260" title="SullyBG , JuliousSA , NichollJ . An investigation of the impact of futility analysis in publicly funded trials. Trials2014;17(15):61. [DOI: 10.1186/1745-6215-15-61] [PMID: 24533447]">Sully 2014</a>). It has also been suggested that the most important therapies adopted in clinical practice have only shown modest benefits (<a href="./references#CD002190-bbs2-0217" title="KirbyA , GebskiV , KeechAC . Determining the sample size in a clinical trial. Medical Journal of Australia2002;177(5):256-7. [PMID: 12197821]">Kirby 2002</a>). </p> </section> <section id="CD002190-sec-0058"> <h3 class="title" id="CD002190-sec-0058">Certainty of the evidence</h3> <p>The results for the primary outcomes of incidence of the common cold and vaccine safety were based on very lowâcertainty evidence due to imprecision because confidence intervals were wide and the number of events was low; indirectness (the RCT considered in our review included only young, healthy men); and methodological limitations. Random sequence generation, allocation, sample size, and baseline characteristics of participants were not reported. Adverse events were not reported individually for each group. Overall, due to a lack of evidence, the balance between the benefits and harms of cold vaccines is uncertain. </p> </section> <section id="CD002190-sec-0059"> <h3 class="title" id="CD002190-sec-0059">Potential biases in the review process</h3> <p>Whilst performing a systematic review, several biases can emerge, such as 'significanceâchasing' biases (<a href="./references#CD002190-bbs2-0207" title="IoannidisJP . Meta-research: the art of getting it wrong. Research Synthesis Methods2010;1(3-4):169-84. [PMID: 26061464]">Ioannidis 2010</a>). This group of biases include publication bias, selective outcome reporting bias, selective analysis reporting bias, and fabrication bias (<a href="./references#CD002190-bbs2-0207" title="IoannidisJP . Meta-research: the art of getting it wrong. Research Synthesis Methods2010;1(3-4):169-84. [PMID: 26061464]">Ioannidis 2010</a>). Publication bias represents a major threat to the validity of systematic reviews, particularly those reviews that include small trials. However, in this systematic review we performed an exhaustive search and attempted to locate all studies to include new RCTs. The current evidence does not evaluate common cold outcomes. </p> </section> <section id="CD002190-sec-0060"> <h3 class="title" id="CD002190-sec-0060">Agreements and disagreements with other studies or reviews</h3> <p>Most studies on vaccines for the common cold evaluate respiratory syncytial virus (RSV) vaccines, followed by studies on adenovirus vaccines; only a few published studies evaluate human rhinovirus (HRV) and parainfluenza vaccines. In addition, these studies mainly aim to reduce lower respiratory tract infections or focus on immunological outcomes. For instance,Â <a href="./references#CD002190-bbs2-0178" title="BuchholzUJ , CunninghamCK , MuresanP , GnanashanmugamD , SatoP , SiberryGK , et al. Live respiratory syncytial virus (RSV) vaccine candidate containing stabilized temperature-sensitivity mutations is highly attenuated in RSV-seronegative infants and children. Journal of Infectious Diseases2018;217(9):1338-46. [DOI: 10.1093/infdis/jiy066] [PMID: 29509929]">Buchholz 2018</a>Â andÂ <a href="./references#CD002190-bbs2-0068" title="McFarlandEJ , KarronRA , MuresanP , CunninghamCK , PerlowskiC , LibousJ , et al. Live-attenuated respiratory syncytial virus vaccine with M2-2 deletion and with small hydrophobic noncoding region is highly immunogenic in children. Journal of Infectious Diseases2020;221(12):2050-9. [DOI: 10.1093/infdis/jiaa049]">McFarland 2020b</a>Â are two RCTs of liveâattenuated RSV vaccines that focus on upper respiratory tract infections; however, these studies assessed immunological outcomes such as vaccine shedding, serum RSV antibodies, antiâRSV F immunoglobulin G, surveillance period, adverse events, and reactogenicity. There is no general consensus on the outcomes to be considered in evaluating the efficacy of a vaccine. In this review we assessed the following outcomes: incidence of common cold after vaccination, vaccine safety, and mortality (all cause and vaccine related), which were not considered in most RCTs assessed for inclusion by full text. We focused on these outcomes due to the impact that the common cold has at the population level, with a high estimated economic loss due to missed working days (<a href="./references#CD002190-bbs2-0215" title="KardosP , MalekFA . Common cold - an umbrella term for acute infections of nose, throat, larynx and bronchi. Pneumologie2017;71(4):221-6. [DOI: 10.1055/s-0042-116112] [PMID: 27912214]">Kardos 2017</a>;Â <a href="./references#CD002190-bbs2-0268" title="TsuzukiS , KimuraY , IshikaneM , KusamaY , OhmagariN . Cost of inappropriate antimicrobial use for upper respiratory infection in Japan. BMC Health Services Research2020;20(1):153. [DOI: 10.1186/s12913-020-5021-1] [PMID: 32111202]">Tsuzuki 2020</a>). Other systematic reviews on vaccines for preventing upper respiratory tract infection have assessed outcomes similar to those included in this review (<a href="./references#CD002190-bbs2-0202" title="HaoQ , DongBR , WuT . Probiotics for preventing acute upper respiratory tract infections. Cochrane Database of Systematic Reviews2015, Issue 2. Art. No: CD006895. [DOI: 10.1002/14651858.CD006895.pub3] [PMID: 25927096]">Hao 2015</a>;Â <a href="./references#CD002190-bbs2-0263" title="ThomasRE , JeffersonT , LassersonTJ . Influenza vaccination for healthcare workers who care for people aged 60 or older living in long-term care institutions. Cochrane Database of Systematic Reviews2013, Issue 7. Art. No: CD005187. [DOI: 10.1002/14651858.CD005187.pub4] [PMID: 23881655]">Thomas 2013</a>).Â  </p> <p>We excluded 11 nonâRCTs that evaluated vaccines for upper respiratory tract infections (<a href="./references#CD002190-bbs2-0008" title="BelsheRB , Van VorisLP , MufsonMA . Parenteral administration of live respiratory syncytial virus vaccine: results of a field trial. Journal of Infectious Diseases1982;145(3):311-9. [PMID: 7037983]">Belshe 1982</a>;Â <a href="./references#CD002190-bbs2-0015" title="ClementsML , BelsheRB , KingJ , NewmanF , WestblomTU , TierneyEL , et al. Evaluation of bovine, cold-adapted human, and wild-type human parainfluenza type 3 viruses in adult volunteers and in chimpanzees. Journal of Clinical Microbiology1991;29(6):1175-82. [PMID: 1650789]">Clements 1991</a>;Â <a href="./references#CD002190-bbs2-0019" title="DoggettJE , BynoeML , TyrrellDA . Some attempts to produce an experimental vaccine with rhinoviruses. British Medical Journal1963;1(5322):34-6. [PMID: 14028369]">Doggett 1963</a>;Â <a href="./references#CD002190-bbs2-0022" title="DuddingBA , BartelloniPJ , ScottRM , Top FH Jr, RussellPK , BuescherEL . Enteric immunization with live adenovirus type 21 vaccine I. Tests for safety, infectivity, immunogenicity, and potency in volunteers. Infection and Immunity1972;5(3):295-9. [PMID: 4564559]">Dudding 1972</a>;Â <a href="./references#CD002190-bbs2-0039" title="FulginitiVA , EllerJJ , SieberOF , JoynerJW , MinamitaniM , MeiklejohnG . Respiratory virus immunization I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. American Journal of Epidemiology1969;89(4):435-48. [PMID: 4305199]">Fulginiti 1969</a>;Â <a href="./references#CD002190-bbs2-0044" title="HamoryBH , HamparianVV , ConantRM , GwaltneyJM . Human responses to two decavalent rhinovirus vaccines. Journal of Infectious Diseases1975;132(6):623-9. [PMID: 172561]">Hamory 1975</a>;Â <a href="./references#CD002190-bbs2-0049" title="KarronRA , WrightPF , CroweJE , Clements-MannML , ThompsonJ , MakheneM , et al. Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children. Journal of Infectious Diseases1997;176(6):1428-36. [PMID: 9395351]">Karron 1997</a>;Â <a href="./references#CD002190-bbs2-0132" title="RitchieJM . Autogenous vaccine in prophylaxis of the common cold. Lancet1958;1(7021):615-8. [PMID: 13515297]">Ritchie 1958</a>;Â <a href="./references#CD002190-bbs2-0148" title="WattPJ , RobinsonBS , PringleCR , TyrrellDA . Determinants of susceptibility to challenge and the antibody response of adult volunteers given experimental respiratory syncytial virus vaccines. Vaccine1990;8(3):231-6. [PMID: 2363300]">Watt 1990</a>;Â <a href="./references#CD002190-bbs2-0151" title="WilsonJS , GrantPJ , MillerDL , TaylorCE , McDonaldJC . Trial of adenovirus vaccine in Royal Air Force recruits. British Medical Journal1960;1(5179):1081-3. [PMID: 13845090]">Wilson 1960</a>;Â <a href="./references#CD002190-bbs2-0152" title="WrightPF , ShinozakiT , FleetW , SellSH , ThompsonJ , KarzonDT . Evaluation of a live, attenuated respiratory syncytial virus vaccine in infants. Journal of Pediatrics1976;88(6):931-6. [PMID: 178852]">Wright 1976</a>). Only one study evaluated the incidence of the common cold (<a href="./references#CD002190-bbs2-0132" title="RitchieJM . Autogenous vaccine in prophylaxis of the common cold. Lancet1958;1(7021):615-8. [PMID: 13515297]">Ritchie 1958</a>), whilst the others focused on immunologic outcomes.Â The study conducted byÂ <a href="./references#CD002190-bbs2-0132" title="RitchieJM . Autogenous vaccine in prophylaxis of the common cold. Lancet1958;1(7021):615-8. [PMID: 13515297]">Ritchie 1958</a>Â prepared an "autologous vaccine" developed from the nasal secretions of 125 healthy volunteers, who were then inoculated with this product, whilst 75 healthy volunteers served as a control. The results showed a lower incidence of common cold in the vaccine group than in the control group. This study was not an RCT and was thus excluded from our review. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD002190-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002190.pub6/media/CDSR/CD002190/urn:x-wiley:14651858:media:CD002190:CD002190-FIG-01" target="_blank"><b></b></a></p> </div><img alt="PRISMA flowchart" data-id="CD002190-fig-0001" src="/cdsr/doi/10.1002/14651858.CD002190.pub6/media/CDSR/CD002190/image_n/nCD002190-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002190.pub6/media/CDSR/CD002190/image_t/tCD002190-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>PRISMA flowchart</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002190.pub6/full#CD002190-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002190.pub6/media/CDSR/CD002190/image_n/nCD002190-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002190-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002190.pub6/media/CDSR/CD002190/urn:x-wiley:14651858:media:CD002190:CD002190-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Screen4Me summary diagram." data-id="CD002190-fig-0002" src="/cdsr/doi/10.1002/14651858.CD002190.pub6/media/CDSR/CD002190/image_n/nCD002190-FIG-02.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002190.pub6/media/CDSR/CD002190/image_t/tCD002190-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Screen4Me summary diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002190.pub6/full#CD002190-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002190.pub6/media/CDSR/CD002190/image_n/nCD002190-FIG-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002190-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002190.pub6/media/CDSR/CD002190/urn:x-wiley:14651858:media:CD002190:CD002190-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages." data-id="CD002190-fig-0003" src="/cdsr/doi/10.1002/14651858.CD002190.pub6/media/CDSR/CD002190/image_n/nCD002190-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002190.pub6/media/CDSR/CD002190/image_t/tCD002190-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002190.pub6/full#CD002190-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002190.pub6/media/CDSR/CD002190/image_n/nCD002190-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002190-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002190.pub6/media/CDSR/CD002190/urn:x-wiley:14651858:media:CD002190:CD002190-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for the included study." data-id="CD002190-fig-0004" src="/cdsr/doi/10.1002/14651858.CD002190.pub6/media/CDSR/CD002190/image_n/nCD002190-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002190.pub6/media/CDSR/CD002190/image_t/tCD002190-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for the included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002190.pub6/full#CD002190-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002190.pub6/media/CDSR/CD002190/image_n/nCD002190-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002190-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002190.pub6/media/CDSR/CD002190/urn:x-wiley:14651858:media:CD002190:CD002190-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Adenovirus vaccines versus placebo, Outcome 1: Incidence of the common cold" data-id="CD002190-fig-0005" src="/cdsr/doi/10.1002/14651858.CD002190.pub6/media/CDSR/CD002190/image_n/nCD002190-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002190.pub6/media/CDSR/CD002190/image_t/tCD002190-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Adenovirus vaccines versus placebo, Outcome 1: Incidence of the common cold </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002190.pub6/references#CD002190-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002190.pub6/media/CDSR/CD002190/image_n/nCD002190-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD002190-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span>Â <span class="table-title">Virus vaccines compared to placebo for preventing the common cold in healthy people</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Virus vaccines compared to placebo for preventing the common cold in healthy people</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> young, healthy men in a military facility<br/><b>Settings:</b> navy training centre<br/><b>Intervention:</b> adenovirus vaccines (live, inactivated type 4, and inactivated type 4 and 7)<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Virus vaccines for preventing the common cold</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Incidence of the common cold</b> </p> <p>Number of participants with common cold by group<br/>Followâup: mean 9 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.95Â </b><br/>(0.45 to 2.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2307<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>ââââ<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Â </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>12 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>11 per 1000</b><br/>(5 to 24) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vaccine safety</b> </p> <p>Followâup: mean 9 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>The study reported that there were no differences between groups in vaccineârelated adverse events. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2307<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Â </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality: vaccine related and all cause</b> â not reported </p> <p>Followâup: mean 9 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>See comments</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The included study did not report this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.Â  </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to unclear risk of bias.<br/><sup>b</sup>Downgraded one level due to indirectness as the study population is only young men.<br/><sup>c</sup>Downgraded one level due to imprecision as confidence intervals are wide, and the number of events is low. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span>Â <span class="table-title">Virus vaccines compared to placebo for preventing the common cold in healthy people</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002190.pub6/full#CD002190-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002190-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span>Â <span class="table-title">Adenovirus vaccines versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Incidence of the common cold <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span>Â <span class="table-title">Adenovirus vaccines versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002190.pub6/references#CD002190-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD002190.pub6&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD002190-note-0014">EspaÃ±ol</a> </li> <li class="section-language"> <a class="" href="fa#CD002190-note-0011">ÙØ§Ø±Ø³Û</a> </li> <li class="section-language"> <a class="" href="fr#CD002190-note-0012">FranÃ§ais</a> </li> <li class="section-language"> <a class="" href="hr#CD002190-note-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD002190-note-0009">æ¥æ¬èª</a> </li> <li class="section-language"> <a class="" href="ko#CD002190-note-0006">íêµ­ì´</a> </li> <li class="section-language"> <a class="" href="ms#CD002190-note-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD002190-note-0013">Polski</a> </li> <li class="section-language"> <a class="" href="th#CD002190-note-0007">à¸ à¸²à¸©à¸²à¹à¸à¸¢</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD002190-note-0005">ç¹é«ä¸­æ</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright Â© 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">Â Â Facebook</a> <a class="a2a_button_x share-button">Â Â X(Twitter)</a> <a class="a2a_button_whatsapp share-button">Â Â WhatsApp</a> <a class="a2a_dd share-button">Â Â View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002190\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002190\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002190\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002190\x2epub6"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002190\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002190\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002190\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002190\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002190\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002190\x2epub6"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002190\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002190\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002190\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002190\x2epub6"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002190\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002190\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002190\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002190\x2epub6"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Qh5938oe&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002190.pub6&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD002190.pub6';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">EspaÃ±ol</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">ÙØ§Ø±Ø³Û</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">FranÃ§ais</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">à¤¹à¤¿à¤¨à¥à¤¦à¥</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">æ¥æ¬èª</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">íêµ­ì´</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">PortuguÃªs</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Ð ÑÑÑÐºÐ¸Ð¹</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">RomÃ¢nÄ</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">à®¤à®®à®¿à®´à¯</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">à¸ à¸²à¸©à¸²à¹à¸à¸¢</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">ç¹é«ä¸­æ</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">ç®ä½ä¸­æ</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD002190.pub6/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD002190.pub6/full/es">EspaÃ±ol</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002190.pub6%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740726677853"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD002190.pub6/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740726677857"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD002190.pub6/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e997c3cdb9368',t:'MTc0MDcyNjY3OC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 